<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2026.1751727</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The comparative diagnostic and therapeutic application value of FAPI PET/CT and <sup>18</sup>F-FDG PET/CT in oncology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Yao</surname><given-names>Yongqi</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3274184/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Zhao</surname><given-names>Jiawei</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Xiao</surname><given-names>Jingjing</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Yujing</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3224769/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Guo</surname><given-names>Xiaotong</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Jingyi</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>Peitao</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Lixuan</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Juzheng</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Yang</surname><given-names>Jinfeng</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Chen</surname><given-names>Chunrong</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="author-notes" rid="fn004"><sup>&#x2021;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name><surname>Jin</surname><given-names>Jiamin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<xref ref-type="author-notes" rid="fn004"><sup>&#x2021;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1990783/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name><surname>Ge</surname><given-names>Bo</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<xref ref-type="author-notes" rid="fn004"><sup>&#x2021;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Urology, The Second Affiliated Hospital of Guilin Medical University</institution>, <city>Guilin</city>, <state>Guangxi</state>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University</institution>, <city>Guilin</city>, <state>Guangxi</state>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff3"><label>3</label><institution>Guangxi Health Commission Key Laboratory of Tumor Immunology and Receptor-Targeted Drug Basic Research, Guilin Medical University</institution>, <city>Guilin</city>, <state>Guangxi</state>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff4"><label>4</label><institution>Department of Limb Trauma and Hand Surgery, Affiliated Hospital of Guilin Medical University</institution>, <city>Guilin</city>, <state>Guangxi</state>,&#xa0;<country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Jiamin Jin, <email xlink:href="mailto:jinjiamin@glmc.edu.cn">jinjiamin@glmc.edu.cn</email>; Bo Ge, <email xlink:href="mailto:1255780337@qq.com">1255780337@qq.com</email></corresp>
<fn fn-type="equal" id="fn003">
<label>&#x2020;</label>
<p>These authors have contributed equally to this work and share first authorship</p></fn>
<fn fn-type="equal" id="fn004">
<label>&#x2021;</label>
<p>These authors have contributed equally to this work and share last authorship</p></fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-28">
<day>28</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>16</volume>
<elocation-id>1751727</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>04</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Yao, Zhao, Xiao, Chen, Guo, Zhang, Wu, Liu, Zhang, Yang, Chen, Jin and Ge.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Yao, Zhao, Xiao, Chen, Guo, Zhang, Wu, Liu, Zhang, Yang, Chen, Jin and Ge</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-28">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Molecular imaging has become central to oncologic diagnosis and therapy assessment. <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) is widely implemented, yet performance is attenuated in tumors with low glycolytic activity or in sites with high physiological uptake. Small-molecule fibroblast activation protein inhibitors (FAPI) enable high-contrast imaging of cancer-associated fibroblasts within the tumor stroma, offering rapid clearance and favorable biodistribution. This review synthesizes clinical and preclinical evidence comparing FAPI PET/CT with<sup>18</sup>F-FDG PET/CT across solid tumors. Head-to-head analyses indicate superior or complementary lesion conspicuity for FAPI in pancreatic ductal adenocarcinoma and colorectal cancer (CRC) &#x2014;especially peritoneal and nodal disease&#x2014;and context-dependent comparability in breast and head-and-neck cancers. Across studies, FAPI demonstrates higher tumor-to-background ratios and improved detection of small or low-FDG-avid lesions, with variable downstream effects on staging and management. We delineate disease-specific scenarios in which multi-tracer strategies may optimize diagnostic yield and propose a framework for integrating FAPI into precision imaging pathways. Priority areas include prospective, adequately powered trials; harmonized acquisition and quantification protocols; and evaluations of cost-effectiveness and theranostic implications.</p>
</abstract>
<kwd-group>
<kwd>comparative study</kwd>
<kwd>FAPI</kwd>
<kwd>FDG</kwd>
<kwd>molecular imaging</kwd>
<kwd>PET/CT</kwd>
<kwd>precise diagnosis</kwd>
<kwd>tumor imaging</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. The research was funded by multiple sources, including the Science and Technology Plan of Guilin (grant numbers: [20230135-1-1]), the Natural Science Foundation of Guangxi Province (grant numbers: [AB25069043], [2023GXNSFAA026061], [2024GXNSFAA010335], [2025GXNSFAA069989]), the National Natural Science Foundation of China (grant numbers: [32360170], [82460158], [82204208], [82460677]), the Independent project of the Guangxi Key Laboratory of Tumor Immunity and Microenvironment Regulation (grant numbers: [203030302516], [203030302212]), Guangxi Provincial College Students&#x2019; innovation and entrepreneurship training program (grant numbers: [202410601019], [202510601049]).</funding-statement>
</funding-group>
<counts>
<fig-count count="3"/>
<table-count count="6"/>
<equation-count count="0"/>
<ref-count count="111"/>
<page-count count="20"/>
<word-count count="10867"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Cancer Imaging and Image-directed Interventions</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>The multimodal integration of positron emission tomography (PET) and computed tomography (CT) allows for simultaneous functional and molecular as well as anatomical evaluation in a single examination, facilitating the transition from research to routine clinical oncology practice (<xref ref-type="bibr" rid="B1">1</xref>). By visualizing metabolic activity, receptor expression, and microenvironmental changes, PET/CT supports staging and restaging, assessment of treatment response, prognostication, and image-guided therapeutic planning (<xref ref-type="bibr" rid="B2">2</xref>). Traditional morphology-based imaging may fail to detect small lesions, overlook inter- and intra-tumor heterogeneity, and perform suboptimally in assessing early biological response, whereas PET/CT addresses these limitations through molecular readouts (<xref ref-type="bibr" rid="B3">3</xref>). <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) remains the cornerstone tracer, supported by globally standardized clinical frameworks (<xref ref-type="bibr" rid="B4">4</xref>). Its mechanism&#x2014;glucose transporter (GLUT)-mediated uptake and hexokinase-mediated trapping&#x2014;enables sensitive detection in glycolytically active tumors (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). Nonetheless, non-specific uptake in inflammation or infection, high physiological background activity, and tumors with low-grade or mucinous histology can lead to false-positive and false-negative results, thereby reducing the accuracy of staging and treatment response assessment, particularly in head and neck, gastrointestinal, pancreaticobiliary, and gynecologic malignancies (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). In recent years, molecular imaging strategies targeting the tumor microenvironment (TME) have advanced rapidly. The fibroblast activation protein (FAP), abundantly expressed on cancer-associated fibroblasts (CAFs) across numerous solid tumors, plays a pivotal role in key biological processes such as extracellular matrix remodeling, angiogenesis, epithelial&#x2013;mesenchymal transition, and immune suppression. Through these functions, FAP has emerged as a compelling target for both diagnostic imaging and therapeutic intervention within the TME (<xref ref-type="bibr" rid="B9">9</xref>). Small-molecule fibroblast activation protein inhibitor (FAPI) probes demonstrate rapid accumulation within tumor tissues and efficient clearance from non-target organs, yielding high tumor-to-background ratios (TBR) alongside favorable <italic>in vivo</italic> pharmacokinetic and dosimetric characteristics. These attributes present a promising approach to overcoming the major limitations associated with <sup>18</sup>F-FDG imaging (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). The clinical translation of FAPI PET/CT has progressed rapidly, with a range of <sup>68</sup>Ga-labeled and next-generation <sup>18</sup>F-labeled FAPI derivatives (e.g., FAPI-04, FAPI-46, FAP-2286, FAPI-RGD) demonstrating superior lesion detection rates and improved tumor-to-background ratios (TBRs) compared to <sup>18</sup>F-FDG across multiple cancer cohorts. These tracers also exhibit complementary diagnostic value in specific tumor types or clinical contexts (<xref ref-type="bibr" rid="B12">12</xref>). Compared with FDG, which depends on glucose metabolism and GLUT1-mediated transport, FAPI PET/CT provides superior specificity and enhanced contrast in detecting tumor microenvironment alterations, including extracellular matrix remodeling, angiogenesis, and immunosuppressive conditions (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Schematic comparison of imaging mechanisms between<sup>18</sup>F-FDG and FAPI in tumor detection.This picture created by MedPeer (<ext-link ext-link-type="uri" xlink:href="https://www.medpeer.cn/">https://www.medpeer.cn/</ext-link>).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1751727-g001.tif">
<alt-text content-type="machine-generated">Illustration of tumor microenvironments and PET imaging techniques. Left side explains \(^{18}F\)-FDG PET with GLUT1 uptake in brain, myocardium, and inflammation, causing high glycolysis and potential false positives. Center shows a cross-section of a tumor with glycolysis enhancement and immunosuppression in rich matrix/stroma zone. Right side details \(^{68}Ga/^{18}F\)-FAPI PET targeting FAP receptors for stromal targeting. Bottom images depict various cancers: lung, ovarian, breast, liver, pancreatic, gastric, and colorectal, with tumors highlighted. A chart compares FDG and FAPI distribution and signal-to-background ratio.</alt-text>
</graphic></fig>
<p>Building on this background, this review aims to systematically compare FAPI PET/CT and <sup>18</sup>F-FDG PET/CT in terms of biological targets, imaging kinetics and dosimetry, lesion detection rates, SUV/TBR metrics, staging and restaging accuracy, and their impact on clinical decision-making. Particular emphasis is placed on evaluating the evidence across distinct tumor types&#x2014;including pancreatic cancer, gastric cancer, biliary tract tumors, mucinous and low-grade malignancies, head and neck squamous cell carcinoma, breast cancer, and CRC&#x2014;as well as in specific clinical contexts such as postoperative or postradiotherapy settings, coexisting inflammation/fibrosis, and resectability assessment. This analysis outlines the strengths and potential limitations of each imaging modality. Through comprehensive evaluation, we seek to define the clinical scenarios in which FAPI or <sup>18</sup>F-FDG should be preferentially or concurrently utilized to establish more personalized and cost-effective molecular imaging strategies.</p>
</sec>
<sec id="s2">
<title>Understanding the science behind FAPI PET/CT and the evolution of its tracers</title>
<p>FAP, a tumor-microenvironment antigen, exhibits high enrichment on CAFs while maintaining minimal expression in normal tissues. The development of quinoline-based small-molecule FAP inhibitors (FAPIs), such as FAPI-02 and FAPI-04 in 2018, facilitated <sup>68</sup>Ga/<sup>18</sup>F radiolabeling and enabled rapid, high-contrast PET/CT imaging with favorable pharmacokinetic and dosimetric profiles (<xref ref-type="bibr" rid="B13">13</xref>). Initial investigations demonstrated high uptake and superior lesion-to-background contrast across multiple solid tumors, with performance exceeding that of <sup>18</sup>F-FDG in specific clinical scenarios&#x2014;such as improved tumor-to-background ratio and TNM upstaging in CRC, alongside heightened sensitivity and TBR in ovarian peritoneal metastases (<xref ref-type="bibr" rid="B14">14</xref>). For clinical deployment <sup>68</sup>Ga-FAPI has been rapidly adopted due to the availability of <sup>68</sup>Ge/ <sup>68</sup>Ga generators, straightforward radiolabeling synthesis, low physiological background activity, and robust tumor uptake across diverse malignancies (<xref ref-type="bibr" rid="B15">15</xref>). While <sup>18</sup>F-labeled tracers, such as FAPI-74, broaden accessibility through centralized production, they have also demonstrated a significant impact on clinical management in specific patient cohorts (<xref ref-type="bibr" rid="B16">16</xref>). These findings support disease-specific head-to-head comparisons that emphasize detection performance, SUV/TBR, and the impact on clinical decisions.</p>
</sec>
<sec id="s3">
<title>The application of FAPI-PET/CT in malignant tumors</title>
<sec id="s3_1">
<title>Respiratory system neoplasms</title>
<sec id="s3_1_1">
<title>Lung cancer</title>
<p>Lung cancer remains the foremost cause of cancer-related mortality globally. Robust evidence indicates that low-dose computed tomography (LDCT) screening in high-risk populations significantly reduces lung cancer&#x2013;specific mortality (<xref ref-type="bibr" rid="B17">17</xref>). FAPI PET/CT visualizes fibroblast activation protein (FAP)&#x2014;expressed on CAFs&#x2014;and augments conventional imaging by mapping stromal activation in the tumor microenvironment. Owing to its high image contrast and typically optimal lesion delineation at approximately one hour post-injection, FAPI PET/CT offers a clinically practical platform for precise tumor staging and definition of thoracic target volumes (<xref ref-type="bibr" rid="B18">18</xref>). At the lesion level, prospective studies indicate that <sup>18</sup>F-FAPI exhibits superior sensitivity (99% vs. 87%), specificity (93% vs. 79%), accuracy (97% vs. 85%), and negative predictive value (97% vs. 70%) compared to <sup>18</sup>F-FDG across primary tumors, nodal involvement, and distant metastases, while maintaining a comparable positive predictive value&#x2014;underscoring its enhanced utility for ruling out disease during whole-body staging (<xref ref-type="bibr" rid="B19">19</xref>). Meta-analyses similarly demonstrate superior aggregated sensitivity for metastatic lesions (0.99 vs. 0.77), whereas sensitivity for primary tumors is comparable between FAPI and FDG (0.98 vs. 0.99). Semi-quantitatively, the target-to-background ratio (TBR) is lower for FAPI than FDG in primary lung tumors (25.3 &#xb1; 14.0 vs. 32.1 &#xb1; 21.1) but higher in metastatic lymph nodes and bone metastases (7.5 &#xb1; 6.6 vs. 5.9 &#xb1; 8.6; 8.6 &#xb1; 5.4 vs. 4.3 &#xb1; 2.3), suggesting enhanced contrast advantages particularly in osseous disease (<xref ref-type="bibr" rid="B20">20</xref>). Pathologic correlation analyses further confirmed significantly higher <sup>18</sup>F-FAPI uptake in mediastinal and hilar lymph nodes (SUV~max~ 10.87 &#xb1; 7.29 vs. 6.08 &#xb1; 5.37), yielding superior diagnostic performance compared to FDG, with respective sensitivity, specificity, accuracy, PPV, and NPV values of 84%, 92%, 90%, 84%, and 92% versus 71%, 67%, 69%, 52%, and 83%. Importantly, for subcentimeter nodes (&lt;10&#xa0;mm), <sup>18</sup>F-FAPI demonstrated enhanced specificity, accuracy, and PPV (96%, 93%, and 77% vs. 72%, 73%, and 33%), underscoring its enhanced reliability in identifying small nodal metastases (<xref ref-type="bibr" rid="B20">20</xref>). In a prospective perioperative cohort, an <sup>18</sup>F-FAPI SUV_max threshold of 6.2 effectively discriminated benign from metastatic lymph nodes (NPV 93.8%; PPV 87.5% in the absence of calcification or high-density features); integration of dual-tracer imaging improved nodal staging accuracy to 83% and led to changes in clinical management for 29 patients (<xref ref-type="bibr" rid="B21">21</xref>). Analysis of real-world NSCLC cohorts reveals comparable primary tumor SUV_max/TBR, yet demonstrates enhanced detection of nodal and osseous metastases with FAPI, leading to cancer stage reclassification in approximately 11% of patients (<xref ref-type="bibr" rid="B22">22</xref>). A subsequent single-center prospective study similarly identified a higher prevalence of suspicious nodal, osseous, and pleural lesions using FAPI compared to FDG (<xref ref-type="bibr" rid="B23">23</xref>). To systematically assess the performance differences between FAPI and <sup>18</sup>F-FDG in oncological imaging, we have synthesized key parameters from current representative studies, enabling a comprehensive comparison of their diagnostic accuracy, tumor targeting efficiency, and clinical applicability (<xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>). Compared with <sup>18</sup>F-FDG, FAPI-PET/CT demonstrates superior sensitivity, specificity, and tumor-to-background ratio (TBR) in N/M staging of lung cancer, particularly for mediastinal and hilar lymph nodes as well as bone, brain, and pleural metastases, while maintaining a comparable overall detection rate for primary lesions. Emerging evidence also suggests that FAPI-PET/CT may reflect the immune microenvironment, such as PD-L1 expression, thereby offering the potential to improve the accuracy of staging and inform more precise treatment decision-making.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Summary of key parameter comparisons (FAPI vs FDG, Lung Cancer).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Indicators/Scenarios</th>
<th valign="middle" align="center">FAPI</th>
<th valign="middle" align="center">FDG</th>
<th valign="middle" align="center">References</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">The sensitivity of all lesion levels</td>
<td valign="middle" align="center">99%</td>
<td valign="middle" align="center">87%</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B19">19</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">The specificity of all lesion levels</td>
<td valign="middle" align="center">93%</td>
<td valign="middle" align="center">79%</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B19">19</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">The accuracy of all lesion levels</td>
<td valign="middle" align="center">97%</td>
<td valign="middle" align="center">85%</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B19">19</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Mean TBR of primary lung tumor</td>
<td valign="middle" align="center">25.3</td>
<td valign="middle" align="center">32.1</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B19">19</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Mean TBR of metastatic lymph nodes</td>
<td valign="middle" align="center">7.5</td>
<td valign="middle" align="center">5.9</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B19">19</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Mean TBR of bone metastasis</td>
<td valign="middle" align="center">8.6</td>
<td valign="middle" align="center">4.3</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B19">19</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Mean TBR of brain metastases</td>
<td valign="middle" align="center">314.4</td>
<td valign="middle" align="center">1</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B23">23</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">The comprehensive sensitivity of mediastinal/hilar lymph nodes</td>
<td valign="middle" align="center">84%</td>
<td valign="middle" align="center">71%</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B20">20</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">The comprehensive specificity of mediastinal/hilar lymph nodes</td>
<td valign="middle" align="center">92%</td>
<td valign="middle" align="center">67%</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B20">20</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Specificity of small lymph nodes (&lt; 10 mm)</td>
<td valign="middle" align="center">96%</td>
<td valign="middle" align="center">72%</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B20">20</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Accuracy of small lymph nodes (&lt; 10 mm)</td>
<td valign="middle" align="center">93%</td>
<td valign="middle" align="center">73%</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B20">20</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Accuracy rate of N stage integration</td>
<td valign="middle" align="center">83%(FAPI+FDG)</td>
<td valign="middle" align="center">Non-direct comparison items</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B21">21</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">The difference in SUV_max/TBR of the primary lesion</td>
<td valign="middle" align="center">No significant differences were observed</td>
<td valign="middle" align="center">No significant differences were observed</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B24">24</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Systemic metastasis detected (LN/bone/pleura)</td>
<td valign="middle" align="center">More</td>
<td valign="middle" align="center">less</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B24">24</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Combined sensitivity of metastatic foci</td>
<td valign="middle" align="center">0.99</td>
<td valign="middle" align="center">0.77</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B25">25</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">PD-L1 correlation (trend)</td>
<td valign="middle" align="center">Positive correlation</td>
<td valign="middle" align="center">Benign inflammatory interference</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B22">22</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Imaging Timing and Dose</td>
<td valign="middle" align="center">1 hour comparison is the best; low effective dose</td>
<td valign="middle" align="center">Benign inflammatory interference</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B18">18</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Benign inflammatory interference</td>
<td valign="middle" align="center">Possibly positive</td>
<td valign="middle" align="center">Possibly positive</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B26">26</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s3_2">
<title>Tumors of the female reproductive system</title>
<sec id="s3_2_1">
<title>Ovarian cancer</title>
<p>Globally, ovarian cancer (OC) is the seventh most commonly diagnosed malignancy in women and ranks as the eighth primary cause of female cancer-related deaths (<xref ref-type="bibr" rid="B27">27</xref>). In epithelial ovarian cancer (EOC), conventional imaging and <sup>18</sup>F-FDG PET/CT often fail to detect small metastatic lymph nodes and peritoneal deposits, highlighting the necessity for tracers with a high tumor-to-background ratio (TBR) to improve staging accuracy and surgical strategy. In a prospective comparative trial, [68Ga]Ga-FAPI-04 and <sup>18</sup>F-FDG demonstrated similar diagnostic performance at the patient level for identifying primary tumors (sensitivity: 93.9% vs 90.9%; specificity: 80.0% vs 80.0%; accuracy: 92.1% vs 89.5%); however, FAPI imaging achieved a markedly higher tumor-to-liver ratio (TLR; median: 15.95 vs 4.94; P &lt; 0.001), indicative of superior lesion contrast due to reduced background uptake (<xref ref-type="bibr" rid="B28">28</xref>). Notably, physiological ovarian FDG uptake fluctuates according to the menstrual cycle, which can compromise diagnostic specificity; in contrast, FAPI uptake exhibits no such cyclical variation (<xref ref-type="bibr" rid="B29">29</xref>). In pathology-correlated studies of peritoneal seeding, FAPI demonstrates consistently superior patient-level sensitivity compared to FDG (97.5% vs. 75.9% and 96.8% vs. 83.0%; both P&#x2009;&lt;&#x2009;0.001), in addition to significantly improved semi-quantitative parameters (SUV_max: 17.31 vs. 13.68, P&#x2009;=&#x2009;0.026; TLR: 23.81 vs. 5.39, P&#x2009;&lt;&#x2009;0.001; PCI: 15 vs. 11, P&#x2009;&lt;&#x2009;0.001) (<xref ref-type="bibr" rid="B28">28</xref>). In patients with platinum-sensitive recurrent disease, FAPI imaging demonstrates a substantial improvement in both sensitivity and accuracy (96.30% vs 49.07% and 97.40% vs 63.87%, respectively), an effect primarily driven by enhanced tumor-to-background ratio rather than by differences in absolute SUV_max (<xref ref-type="bibr" rid="B30">30</xref>). Lesion-distribution analyses further indicate enhanced detection of peritoneal and pleural metastases (e.g., 9/9 vs. 5/9) and occasional upstaging, underscoring the additional value of this approach for systemic staging (<xref ref-type="bibr" rid="B31">31</xref>). For the assessment of diaphragmatic and upper abdominal dissemination, FAPI-PET/MR imaging benefits from a low hepatic background, yields peritoneal carcinomatosis index estimates that align more closely with surgical observations, and enhances the prediction of incomplete cytoreduction (sensitivity: 91.67%; specificity: 64.29%) (<xref ref-type="bibr" rid="B32">32</xref>). Consistent systematic evidence across gynecologic malignancies reveals a superior pooled sensitivity for detecting peritoneal cancer with FAPI (approximately 0.98) compared to FDG (0.71), accompanied by reduced background signal and an increased tumor-to-background ratio (<xref ref-type="bibr" rid="B33">33</xref>). Collectively <sup>68</sup>Ga-FAPI PET/CT provides enhanced contrast and superior sensitivity for detecting peritoneal implants and specific nodal metastases in ovarian cancer (OC), whereas FDG retains utility for metabolic characterization; a dual-tracer approach may thus more comprehensively capture complementary molecular&#x2013;mesenchymal phenotypes and refine clinical decision-making (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Clinically, FAPI-guided staging resulted in upstaging of disease in a substantial proportion of patients (14.3% in newly diagnosed and 33.3% in recurrent EOC), which consequently altered clinical management in 10.7% and 19.0% of cases, respectively. These findings support the preferential application of FAPI imaging for evaluating suspected peritoneal seeding, assessing resectability, and monitoring recurrence, although definitive recommendations await larger prospective trials investigating long-term patient outcomes (<xref ref-type="bibr" rid="B28">28</xref>). To systematically present the comparative performance of FAPI and <sup>18</sup>F-FDG across key parameters in ovarian cancer, this article summarizes and synthesizes the available research data (<xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref>). Current head-to-head and meta-analytic evidence indicates that <sup>68</sup>Ga-FAPI PET/CT demonstrates a higher detection rate and significantly improved tumor-to-background ratio (TBR) compared to <sup>18</sup>F-FDG PET/CT in the evaluation of ovarian cancer, particularly for peritoneal implants and selected lymph node metastases. In various clinical scenarios, the SUV_max values obtained with FAPI are at least comparable to, and in some cases higher than, those of FDG. This contributes to more accurate staging and enhanced clinical decision-making potential.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Summary of key parameter comparisons (FAPI vs FDG, Ovarian Cancer).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Indicators/Scenarios</th>
<th valign="middle" align="center">FAPI</th>
<th valign="middle" align="center">FDG</th>
<th valign="middle" align="center">References</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">Primary lesion sensitivity (patient level)</td>
<td valign="middle" align="center">100%(11/11)</td>
<td valign="middle" align="center">100%(11/11)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Primary lesion sensitivity (lesion/preoperative)</td>
<td valign="middle" align="center">100%(14/14)</td>
<td valign="middle" align="center">90%(9/10)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Sensitivity of recurrent lesions (lesion level)</td>
<td valign="middle" align="center">96.30%</td>
<td valign="middle" align="center">49.07%</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B30">30</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Accuracy of recurrent lesions (lesion level)</td>
<td valign="middle" align="center">97.40%</td>
<td valign="middle" align="center">63.87%</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B30">30</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Peritoneal metastasis sensitivity (patient level)</td>
<td valign="middle" align="center">95.00%</td>
<td valign="middle" align="center">83.33%</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Peritoneal metastasis sensitivity (region/focus)</td>
<td valign="middle" align="center">90.16%</td>
<td valign="middle" align="center">60.66%</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Detection rate of peritoneal metastasis (comparison within the study)</td>
<td valign="middle" align="center">96.80%</td>
<td valign="middle" align="center">83.00%</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B28">28</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Peritoneal/pleural metastasis sensitivity (lesions, small sample)</td>
<td valign="middle" align="center">100%(9/9)</td>
<td valign="middle" align="center">56%(5/9)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B31">31</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Peritoneal metastasis SUVmax (mean/median)</td>
<td valign="middle" align="center">17.31</td>
<td valign="middle" align="center">13.68</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B28">28</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Peritoneal metastasis TBR (median)</td>
<td valign="middle" align="center">7.55</td>
<td valign="middle" align="center">2.7</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Lymph node metastasis sensitivity (lesion/pathological basis)</td>
<td valign="middle" align="center">80.60%</td>
<td valign="middle" align="center">61.30%</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B28">28</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Lymph node-specific (lesion/pathological benchmark)</td>
<td valign="middle" align="center">95.10%</td>
<td valign="middle" align="center">96.10%</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B28">28</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">The maximum SUV of lymph nodes (posterior abdominal/above the diaphragm)</td>
<td valign="middle" align="center">8.72/6.39</td>
<td valign="middle" align="center">6.56/4.20</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B28">28</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Mean &#xb1; SD of TBR in lymph nodes</td>
<td valign="middle" align="center">11.13 &#xb1; 9.59</td>
<td valign="middle" align="center">3.24 &#xb1; 3.12</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B30">30</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">The overall TBR (mean &#xb1; SD) of recurrent lesions</td>
<td valign="middle" align="center">7.50 &#xb1; 6.42</td>
<td valign="middle" align="center">3.19 &#xb1; 2.96</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B30">30</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Tumor burden (Eisenkop score)</td>
<td valign="middle" align="center">27</td>
<td valign="middle" align="center">16</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B30">30</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Change in treatment strategy (recurrence cohort)</td>
<td valign="middle" align="center">17.24% of the patients had their treatment adjusted based on FAPI information.</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B30">30</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Figure caption example:-:No data.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="s3_3">
<title>Tumors of the mammary system</title>
<sec id="s3_3_1">
<title>Breast cancer</title>
<p>Despite notable advances in cancer research, breast cancer remains a significant global health challenge and continues to be a central focus of biomedical investigation (<xref ref-type="bibr" rid="B34">34</xref>). Fibroblast activation protein (FAP), which is highly expressed in CAFs of the breast tumor stroma, permits FAPI-based tracers to achieve elevated tumor uptake alongside a low physiological background. This results in an enhanced tumor-to-background ratio (TBR) and improved lesion conspicuity, especially for sub-centimeter lesions and areas with minimal inflammatory activity (<xref ref-type="bibr" rid="B35">35</xref>). In a prospective head-to-head comparison involving 34 newly diagnosed patients, FAPI exhibited significantly higher SUV_max and tumor-to-background ratio (TBR) in primary lesions compared to FDG (SUV_max: 11.06 &#xb1; 5.48 vs. 8.33 &#xb1; 6.07; TBR: 15.32 &#xb1; 10.33 vs. 8.25 &#xb1; 5.51; both statistically significant). Moreover, FAPI SUV_max showed a positive correlation with pathological grade and clinical stage, while lesion-level detection rates were 100% (50/50) for FAPI versus 96% (48/50) for FDG (<xref ref-type="bibr" rid="B36">36</xref>). In a separate comparative analysis employing direct TBR quantification, primary lesions exhibited a significantly higher median TBR with FAPI than with FDG (14.8 versus 6.3, p = 0.002) (<xref ref-type="bibr" rid="B35">35</xref>). For the assessment of lymph node metastasis, FAPI demonstrated superior specificity and diagnostic accuracy compared to FDG, achieving a higher overall N-staging accuracy (91.2% vs 73.5%) and enhanced detection of axillary N0 status (85.7% vs 42.9%) (<xref ref-type="bibr" rid="B36">36</xref>). In low-FDG-avid disease subgroups, FAPI imaging can detect additional nodal involvement in the axillary, supraclavicular, and mediastinal regions, including subcentimeter nodes that are solely FAPI-positive, with potential implications for disease upstaging (<xref ref-type="bibr" rid="B37">37</xref>). The comparatively low physiological uptake of FAPI in normal bone and brain tissue results in higher target-to-background ratios and superior visualization of osseous and cerebral metastases compared to FDG (<xref ref-type="bibr" rid="B35">35</xref>). In cases of liver metastases, while SUV_max values may be comparable, FAPI significantly enhances the tumor-to-background ratio and enables the detection of lesions not visible on FDG-PET, owing to its minimal physiological uptake in normal liver tissue (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B38">38</xref>). Paired multi-cohort analyses indicate that FAPI and FDG exhibit comparable patient-level diagnostic accuracy in breast cancer, albeit with limitations due to small sample sizes, while regional sensitivity and accuracy are largely similar. Nevertheless, a modestly lower negative predictive value (NPV) observed with FAPI may indicate underlying heterogeneity among biological subtypes and lesion stages (<xref ref-type="bibr" rid="B39">39</xref>). Notably, FAPI imaging can yield false-positive results in the context of fibrotic or granulomatous lesions, highlighting the necessity for comprehensive clinical correlation and multimodal imaging integration (<xref ref-type="bibr" rid="B40">40</xref>). Collectively, FAPI imaging represents a valuable adjunct to FDG for initial breast cancer staging, particularly in confirming axillary N0 status, refining evaluation in cases with low FDG avidity, and improving the detection of brain, bone, and hepatic metastases (<xref ref-type="bibr" rid="B35">35</xref>&#x2013;<xref ref-type="bibr" rid="B37">37</xref>). In summary, FAPI PET/CT demonstrates higher SUV_max and tumor-to-background ratio (TBR) compared to <sup>18</sup>F-FDG in both primary breast cancer lesions and multi-organ metastases, particularly in axillary N0 staging, low FDG-avid subtypes, and metastases involving the liver, bone, and brain. Furthermore, FAPI PET/CT delivers at least non-inferior and potentially superior diagnostic performance.</p>
</sec>
</sec>
<sec id="s3_4">
<title>Solid tumors of the digestive system</title>
<sec id="s3_4_1">
<title>Liver cancer</title>
<p>Primary liver cancer is the fourth leading cause of cancer-related deaths worldwide. Histologically, liver cancer is primarily categorized into two major subtypes: hepatocellular carcinoma, which accounts for approximately 75% of all cases, and ICC, representing about 15% of all liver cancers (<xref ref-type="bibr" rid="B41">41</xref>). While <sup>18</sup>F-FDG PET, which reflects glucose metabolism, typically demonstrates low or heterogeneous uptake in well-to-moderately differentiated hepatocellular carcinoma (HCC) and certain ICC subtypes, its diagnostic utility is constrained by high physiological liver activity, resulting in a suboptimal tumor-to-background ratio (TBR). Conversely, FAPI imaging targets CAFs in the tumor microenvironment, leading to low background activity in normal liver parenchyma and elevated uptake in fibrosis-rich or stroma-dense tumors, thereby enhancing lesion detectability. However, the potential for false-positive findings due to benign inflammatory processes necessitates correlative interpretation with anatomical imaging and clinical context (<xref ref-type="bibr" rid="B42">42</xref>). In a prospective observational cohort (n=44), <sup>18</sup>F-FAPI-04 exhibited superior sensitivity relative to <sup>18</sup>F-FDG in detecting malignant liver lesions (84.6% [33/39] vs 76.9% [30/39]), albeit with reduced specificity (60% [3/5] vs 100% [5/5]), accompanied by significantly elevated SUV_max and tumor-to-background ratio (TBR) values (<xref ref-type="bibr" rid="B43">43</xref>). A head-to-head comparative study, stratified by histology, revealed a superior overall sensitivity for FAPI (96% [22/23]) compared with FDG (65% [15/23]), with specific improvements observed in both hepatocellular carcinoma (94% vs 69%) and ICC (100% vs 57%) (<xref ref-type="bibr" rid="B42">42</xref>). At the lesion level, FAPI demonstrated superior performance compared to FDG (85.7% vs. 57.1%), especially in detecting small lesions &#x2264;2 cm (68.8% vs. 18.8%) and moderately to well-differentiated hepatocellular carcinoma (83.3% vs. 33.3%) (<xref ref-type="bibr" rid="B44">44</xref>). <sup>18</sup>F-FAPI demonstrates a greater influence on the initial staging and therapeutic decision-making for hepatocellular carcinoma (HCC), as it enables the detection of more primary lesions and lymph node or peritoneal metastases, leading to T-stage upstaging. However, <sup>18</sup>F-FDG retains certain advantages in assessing large vessel invasion and selected bone metastases (<xref ref-type="bibr" rid="B45">45</xref>). FAPI demonstrates significantly higher sensitivity and detection rates compared to FDG, particularly in early-stage or small-volume lesions and high-to-moderately differentiated hepatocellular carcinoma (HCC). However, its specificity is moderately lower than that of FDG due to inflammatory false-positive findings, necessitating the incorporation of multi-modal imaging and clinical evidence for accurate interpretation (<xref ref-type="bibr" rid="B43">43</xref>). The median SUV_max/TBR was also significantly higher with FAPI (13.61/5.55) than with FDG (4.24/1.17), a finding that extended to intrahepatic cholangiocarcinoma (TBR 6.95 vs. 1.49). Notably, FAPI-derived metrics increased progressively with worsening hepatocellular carcinoma differentiation, whereas FDG uptake failed to show clear stratification, underscoring the biological complementarity of the two imaging approaches (<xref ref-type="bibr" rid="B42">42</xref>). In mixed hepatocellular&#x2013;cholangiocarcinoma, Ki-67 expression exhibited a positive correlation with FAPI-SUV_max (R = 0.603), and specific immunophenotypes were linked to elevated FAPI uptake, whereas no significant associations were observed for FDG-derived metrics. Mild hepatic fibrosis or steatosis may lead to a modest increase in FAPI background activity, thereby attenuating improvements in tumor-to-background ratio (TBR). In addition, the presence of inflammatory pseudotumors or dysplastic nodules can compromise diagnostic specificity, as illustrated by a reduction from 100% to 60% in certain cases (<xref ref-type="bibr" rid="B43">43</xref>). For whole-body staging, FAPI imaging identified a greater number of peritoneal and osseous lesions (e.g., peritoneum: 12 vs 4; bone: 43 vs 33), yet demonstrated no distinct superiority in the detection of pulmonary metastases, indicating complementary patterns of metastatic involvement (<xref ref-type="bibr" rid="B42">42</xref>). Collectively, FAPI demonstrates superior sensitivity, SUV_max, and tumor-to-background ratio in liver tumors, aligning with existing comparative data (<xref ref-type="bibr" rid="B46">46</xref>). Prospective data substantiate the utility of this approach for small-volume and well-to-moderately differentiated HCC, while FDG-PET may more effectively delineate specific invasive and metastatic characteristics; the integration of dual-tracer imaging strategies could enhance initial staging accuracy and refine management planning (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>). Therefore, FAPI-PET/CT should be prioritized in the initial staging, recurrence evaluation, and systemic metastasis characterization of HCC and ICCC, particularly in scenarios where MRI/CT findings are suspicious but FDG shows negative or low uptake, or when a high tumor-to-background ratio (TBR) is required for the assessment of small lesions or those dominated by interstitial reactions. For suspected inflammatory lesions or cases with significant liver fibrosis, complementary use of MRI, multiparametric CT, and clinical-pathological parameters is recommended to enhance diagnostic specificity.</p>
</sec>
<sec id="s3_4_2">
<title>Pancreatic cancer</title>
<p>Pancreatic cancer remains among the most lethal malignancies worldwide. According to the GLOBOCAN 2012 estimates, it accounts for more than 331,000 annual deaths, ranking as the seventh leading cause of cancer-related mortality in both men and women (<xref ref-type="bibr" rid="B47">47</xref>). In pancreatic cancer, predominantly pancreatic ductal adenocarcinoma (PDAC), FAPI-PET/CT, which targets the CAF-mediated stromal response, demonstrates consistently superior overall diagnostic performance compared to <sup>18</sup>F-FDG PET/CT, which relies on glucose metabolism. Accumulating evidence from previous systematic reviews indicates that FAPI offers improved detection rates and enhanced quantitative contrast,as reflected by higher SUV and TBR values, across primary tumors, lymph node metastases, distant metastatic lesions, and peritoneal implants (<xref ref-type="bibr" rid="B48">48</xref>,&#xa0;<xref ref-type="bibr" rid="B49">49</xref>). A meta-analysis focusing specifically on pancreatic ductal adenocarcinoma (PDAC), which included 7 studies and 322 patients, demonstrated a significantly higher pooled sensitivity for FAPI compared to FDG (0.99 [0.97&#x2013;1.00] versus 0.84 [0.70&#x2013;0.92]), while specificity remained comparable (0.84 [0.63&#x2013;0.94] versus 0.85 [0.75&#x2013;0.91]). The analysis also revealed a larger area under the curve (AUC) for FAPI (0.99 [0.98&#x2013;1.00] versus 0.91 [0.88&#x2013;0.93]). This superiority was consistent at both the patient and lesion levels, especially for nodal and distant metastases, and FAPI exhibited a higher SUV_max in primary lesions, with a mean difference of +6.47 (<xref ref-type="bibr" rid="B49">49</xref>). Consistent findings across multiple cohorts further validate the superior tumor-to-background ratio (TBR) achieved with FAPI, exemplified by enhanced contrast in liver metastases (e.g., TBR 5.7 &#xb1; 3.2 versus 3.2 &#xb1; 1.3), underscoring its utility in improving lesion detectability in low-contrast imaging scenarios (<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>). Prospective head-to-head comparative studies (including those utilizing <sup>18</sup>F-AIF-FAPI-74) reveal significantly lower background uptake (median SUVmean 0.8 versus 2.6) and superior tumor-to-background ratios, thereby enhancing the detection of small-volume nodal metastases and peritoneal implants and improving the certainty of staging evaluations (<xref ref-type="bibr" rid="B51">51</xref>). The superior imaging capabilities yield clinically significant impacts on staging and management: single-institution studies report nodal upstaging rates as high as 51.6% and alterations in treatment plans in up to 38.7% of cases, whereas pooled analyses reveal overall staging reclassification and management modification rates of 25% and 11.7%, respectively (<xref ref-type="bibr" rid="B49">49</xref>). In a prospective comparative study of <sup>18</sup>F-FAPI-04 and FDG, TNM staging was upstaged in 14 out of 62 patients, highlighting the enhanced utility of FAPI for perioperative staging and the evaluation of resectability (<xref ref-type="bibr" rid="B51">51</xref>). Beyond staging, baseline imaging phenotypes, including the &#x201c;distal pancreatitis&#x201d; sign, can signal ductal obstruction, greater metastatic burden, and poorer prognosis; quantitatively, in a cohort of 51 patients, a FAPI-SUV_max threshold of 14.9 independently stratified overall survival (hazard ratio 8.877), suggesting that stroma-targeted tracer uptake intensity may reflect aggressive tumor biology and facilitate risk stratification (<xref ref-type="bibr" rid="B50">50</xref>). To systematically present the comparative performance of FAPI and <sup>18</sup>F-FDG across key parameters in&#xa0;pancreatic cancer, this article summarizes and synthesizes the&#xa0;available research data (<xref ref-type="table" rid="T3"><bold>Table&#xa0;3</bold></xref>). Overall, FAPI-PET/CT demonstrates consistent advantages over FDG in sensitivity and image contrast for both primary and metastatic lesions in pancreatic cancer, while exhibiting comparable specificity. These characteristics suggest its potential to transform perioperative staging and recurrence monitoring workflows in pancreatic cancer management. Further validation in multicenter prospective trials is warranted to explore complementary strategies with FDG,&#xa0;such as delayed imaging and multi-tracer combinations, to&#xa0;optimize real-world clinical decision-making. Specifically, in&#xa0;pancreatic cancer, FAPI-PET/CT outperforms <sup>18</sup>F-FDG in terms of sensitivity and tumor-to-background ratio (TBR) for&#xa0;detecting primary tumors, lymph node involvement, and distant metastases, without compromising specificity, thereby improving the accuracy of TNM staging and the formulation of treatment strategies.</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Summary of key parameter comparisons (FAPI vs FDG, Pancreatic Cancer).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Indicators/Scenarios</th>
<th valign="middle" align="left">FAPI</th>
<th valign="middle" align="left">FDG</th>
<th valign="middle" align="left">References</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Merged sensitivity</td>
<td valign="middle" align="left">0.99(0.97&#x2013;1.00)</td>
<td valign="middle" align="left">0.84(0.70&#x2013;0.92)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Specificity of combination</td>
<td valign="middle" align="left">0.84(0.63&#x2013;0.94)</td>
<td valign="middle" align="left">0.85(0.75&#x2013;0.91)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Area under the ROC curve</td>
<td valign="middle" align="left">0.99(0.98&#x2013;1.00)</td>
<td valign="middle" align="left">0.91(0.88&#x2013;0.93)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">SUV_max of primary lesion (mean difference/weighted mean difference)</td>
<td valign="middle" align="left">6.47</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Primary lesion sensitivity (patient level)</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">0.94</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Lymph node sensitivity (patient level)</td>
<td valign="middle" align="left">0.96</td>
<td valign="middle" align="left">0.66</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Distant liver metastasis sensitivity (patient level)</td>
<td valign="middle" align="left">1.00/1.00</td>
<td valign="middle" align="left">0.75/0.80</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Background SUV median</td>
<td valign="middle" align="left">0.8(median)</td>
<td valign="middle" align="left">2.6(median)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Primary lesion TBR (blood pool reference)</td>
<td valign="middle" align="left">6.9 &#xb1; 2.5;4.4 &#xb1; 3.8</td>
<td valign="middle" align="left">2.6 &#xb1; 1.3;4.0 &#xb1; 2.6</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">TBR of liver metastasis</td>
<td valign="middle" align="left">5.7 &#xb1; 3.2</td>
<td valign="middle" align="left">3.2 &#xb1; 1.3</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Change in TNM staging (combined/single center upper limit)</td>
<td valign="middle" align="left">25%; up to 51.6%</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Clinical management changes (combined/single center upper limit)</td>
<td valign="middle" align="left">11.7%; up to 38.7%</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Individual studies on TNM upregulation</td>
<td valign="middle" align="left">14/62(23%)</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B49">49</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Prognostic threshold (SUV_max)</td>
<td valign="middle" align="left">14.9(HR 8.877)</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Figure caption example:-:No data.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_4_3">
<title>Gastric cancer</title>
<p>Less than a century ago, gastric cancer was the most common malignancy in the United States and globally. Despite a significant decline in its global incidence over the past century, it remains a leading cause of cancer-related mortality worldwide (<xref ref-type="bibr" rid="B52">52</xref>). In contrast to <sup>18</sup>F-FDG, FAPI enables superior tumor-to-background contrast in gastric cancer by specifically targeting CAFs, while exhibiting minimal physiologic uptake in the gastrointestinal tract, thereby allowing more precise disease staging and therapy-response evaluation (<xref ref-type="bibr" rid="B53">53</xref>&#x2013;<xref ref-type="bibr" rid="B55">55</xref>). In prospective, head-to-head analyses of newly diagnosed cohorts, FAPI demonstrated a primary-tumor detection rate of 100%, compared with 50.0% for FDG; a separate prospective PET/MR study similarly revealed superior performance for FAPI (86.7% vs 60.0%) (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>). Quantitatively, FAPI demonstrates significantly higher radiotracer uptake and superior contrast, as evidenced by elevated median SUVmax (10.3 vs. 8.1) and tumor-to-background ratio (TBR; 11.6 vs. 5.8). These findings are corroborated by a separate prospective cohort, which reported a further increased TBR (11.9 vs. 3.2). Additionally, FAPI exhibits consistently higher tumor-to-liver ratios (TLR) across various anatomical regions (<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B58">58</xref>). In the evaluation of lymph node metastasis, FAPI demonstrates enhanced sensitivity, specificity, and overall diagnostic performance. Nodule-based analysis revealed that the sensitivity of FDG is 54%, whereas FAPI achieves a significantly higher sensitivity of 79%. A retrospective cohort analysis further showed that FAPI exhibits an accuracy of 92.2%, sensitivity of 78.6%, and specificity of 96.0% for lymph node staging, all of which are either superior to or non-inferior to FDG. Notably, when validated against pathological/surgical findings, FAPI shows significantly higher specificity and positive predictive value compared to FDG (100.0% vs. 97.7%; 100.0% vs. 57.1%, respectively) (<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B59">59</xref>). For peritoneal dissemination, intra-patient comparative analyses reveal a marked superiority of FAPI (detection rate 100% vs. 0%; mean SUVmax 10.0 vs. 2.4). Furthermore, a study published in EJNMMI documented a greater number of detected lesions and a higher tumor-to-background ratio (TBR) with FAPI (159 vs. 47 lesions; TBR 8.1 vs. 3.2). These findings are corroborated by systematic reviews and meta-analyses, which consistently report enhanced sensitivity and improved SUVmax and TBR values for the detection of peritoneal disease (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B58">58</xref>). FAPI demonstrates particular utility in mucinous adenocarcinoma and signet ring cell carcinoma (SRCC), tumor types that are frequently &#x201c;metabolically cold&#x201d; on FDG&#x2013;PET imaging; comparative studies and case evidence in SRCC indicate that FAPI can detect lesions, including peritoneal deposits, that are not visualized by FDG (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B61">61</xref>). Nevertheless, FDG avidity may be diminished in early-stage malignancies and micro-foci characterized by limited volume or shallow infiltration, scenarios in which FDG-PET may retain diagnostic value and dual-tracer approaches could serve a complementary role (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B60">60</xref>). For the early assessment of treatment response, a reduction of &#x2265;52% in both %SUVmax and %TBR on FAPI imaging after a single cycle of neoadjuvant chemotherapy serves as a predictor of major pathological response (AUC 0.856&#x2013;0.864; accuracy ~89.3%), with performance superior to that of FDG-derived parameters (<xref ref-type="bibr" rid="B54">54</xref>). Overall, FAPI-PET/CT demonstrates superior performance to FDG in detecting primary tumors, assessing peritoneal dissemination, and staging lymph node involvement, positioning it for broader application in radiotherapy target delineation and individualized therapeutic monitoring (<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B58">58</xref>). In summary, FAPI-PET/CT demonstrates consistently superior performance compared to <sup>18</sup>F-FDG-PET/CT in the detection of primary gastric cancer lesions, particularly in subtypes with low glucose metabolism and peritoneal metastases, as evidenced by improved imaging contrast&#x2014;most notably tumor-to-background ratio (TBR). FAPI is capable of clearly visualizing signet ring cell carcinomas that exhibit negative or low FDG uptake, thereby influencing disease staging. The implementation of high-quality, standardized prospective studies, along with broader clinical adoption of FAPI, is anticipated to further improve its clinical accessibility and elevate its level of evidence.</p>
</sec>
<sec id="s3_4_4">
<title>Colorectal cancer</title>
<p>CRC now ranks as the fourth most common cause of cancer-related deaths globally, accounting for approximately 900,000 fatalities each year, the expansion of screening programs is intended to enhance early detection and lower both disease incidence and mortality (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>). By specifically targeting fibroblast activation protein (FAP) within the tumor stroma, FAPI demonstrates pronounced tumor uptake while exhibiting minimal physiological background signal in the intestinal lumen and peritoneal cavity, thereby offering a high-contrast platform for CRC&#xa0;staging and metastasis assessment (<xref ref-type="bibr" rid="B64">64</xref>). For the detection of primary lesions, head-to-head comparisons and meta-analyses reveal that FAPI and FDG exhibit comparable diagnostic performance (relative risk &#x2248; 0.99) (<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>). Notwithstanding comparable SUVmax values (14.3 &#xb1; 8.6 vs. 15.4 &#xb1; 9.8, P = 0.604), FAPI demonstrates superior visualization of mucinous adenocarcinoma and signet ring cell carcinoma, achieving a significantly higher tumor-to-background ratio (<xref ref-type="bibr" rid="B64">64</xref>). Nodal evaluation demonstrates superior performance for FAPI, with surgically validated studies reporting sensitivities and specificities for lymph node detection as high as 90% and 100%, respectively, compared to 80% and 81.8% for FDG (<xref ref-type="bibr" rid="B66">66</xref>). The conclusion was further substantiated by lesion-level analyses, which indicated a significant advantage for FAPI (relative risk = 0.63, 95% confidence interval: 0.47&#x2013;0.84) (<xref ref-type="bibr" rid="B65">65</xref>). Analysis of patient-level gastrointestinal cohorts further revealed that FAPI imaging achieved superior accuracy and sensitivity in determining nodal status compared to conventional methods (92.2% vs. 70.3% and 78.6% vs. 71.4%, respectively) (<xref ref-type="bibr" rid="B53">53</xref>). This finding is consistent with the heightened sensitivity observed in the digestive-tract subgroup (79% vs. 54%) (<xref ref-type="bibr" rid="B61">61</xref>). For distant metastases, the low hepatic background activity of FAPI may enhance the detection of small liver metastases; paired data in CRC revealed a greater number of liver lesions with FAPI compared to FDG (13 versus 7) (<xref ref-type="bibr" rid="B65">65</xref>). The paired CRC cohort demonstrated that FAPI identified more liver metastases (13 vs. 7) compared to FDG, indicating a potential clinical advantage in lesion detection. FAPI exhibited its most pronounced superiority in the detection of peritoneal metastases. The CRC study showed that FAPI not only detected a greater number of peritoneal lesions (107 vs. 45), but also yielded higher peritoneal cancer index (PCI) scores (median: 11 vs. 4). Findings from the recurrent CRC study further confirmed that FAPI outperformed FDG in both the detection of peritoneal metastases and PCI assessment, with a higher area under the ROC curve observed in the same patient cohort (<xref ref-type="bibr" rid="B67">67</xref>). Quantitative evaluation of peritoneal tumor burden using FDG-PET/CT is not recommended (<xref ref-type="bibr" rid="B68">68</xref>). Overall, FAPI enhances the assessment of metastatic burden and staging precision, can lead to TNM upstaging, and may influence therapeutic decision-making (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B69">69</xref>). Using a mixed cohort of gastric and CRC as an example, FAPI demonstrates superior performance in detecting distant metastases, which enhances the accuracy of overall staging determination and consequently improves staging precision and clinical stratification (<xref ref-type="bibr" rid="B53">53</xref>). Quantitatively, FAPI generally yields superior tumor-to-background and tumor-to-liver ratios, whereas the maximum standardized uptake value (SUVmax) is frequently similar across different tracers (<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B66">66</xref>) Registry data across various tumor types further indicate a superior overall diagnostic accuracy for CRC (<xref ref-type="bibr" rid="B39">39</xref>). From a biological perspective, these benefits are likely attributable to a high affinity for the CAF-rich tumor stroma, supporting the future incorporation of theranostic approaches in CRC (<xref ref-type="bibr" rid="B70">70</xref>). To systematically present the comparative performance of FAPI and <sup>18</sup>F-FDG across key parameters in CRC, this article summarizes and synthesizes the available research data (<xref ref-type="table" rid="T4"><bold>Table&#xa0;4</bold></xref>). In conclusion, in CRC, FAPI-PET/CT demonstrates superior tumor-to-background ratios&#x2014;particularly in the peritoneum and liver parenchyma with low background activity&#x2014;and exhibits enhanced sensitivity for detecting peritoneal dissemination and lymph node metastases. It also shows greater diagnostic performance in mucinous and signet ring cell subtypes and is capable of identifying small-volume liver metastases. These advantages increase the likelihood of TNM stage upstaging and facilitate treatment strategy modifications. FAPI-PET/CT should be considered as a preferred imaging modality in clinical scenarios involving suspected peritoneal metastasis, <sup>18</sup>F-FDG-negative or equivocal findings, mucinous histology, or recurrence restaging. FAPI-PET/CT offers the potential for more stable contrast enhancement and reproducible quantitative assessment.</p>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>Summary of key parameter comparisons (FAPI vs FDG, Colorectal Cancer).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Detection rate of primary lesion (FAPI vs FDG)</th>
<th valign="middle" align="left">Primary SUVmax (FAPI vs FDG)</th>
<th valign="middle" align="left">Primary contrast (TBR/TLR, FAPI vs FDG)</th>
<th valign="middle" align="left">Lymph node assessment (sensitivity/specificity/accuracy)</th>
<th valign="middle" align="left">Peritoneal metastasis (detection/sensitivity)</th>
<th valign="middle" align="left">Peritoneal contrast (SUVmax or TBR/TLR, FAPI vs FDG)</th>
<th valign="middle" align="left">References</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">100% vs 100%</td>
<td valign="middle" align="left">Lower vs. higher (P &lt; 0.001)</td>
<td valign="middle" align="left">higher(P=0.008)</td>
<td valign="middle" align="left">90%/100%/95% vs 80%/81.8%/80.5%</td>
<td valign="middle" align="left">FAPI was significantly superior, with a sensitivity of approximately 100% versus 55%.</td>
<td valign="middle" align="left">TBR was significantly higher</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B66">66</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">100% vs 93.8%</td>
<td valign="middle" align="left">14.3 &#xb1; 8.6 vs 15.4 &#xb1; 9.8(P=0.604)</td>
<td valign="middle" align="left">19.0 &#xb1; 10.4 vs 11.8 &#xb1; 7.8(P=0.001)</td>
<td valign="middle" align="left">87.5%/87.5%/87.5% vs 87.5%/75.0%/81.3%</td>
<td valign="middle" align="left">Number of lesions 107 vs 45;PCI 11 vs 4(All P &lt; 0.001)</td>
<td valign="middle" align="left">SUVmax 9.0 &#xb1; 7.9 vs 2.6 &#xb1; 1.7;TBR 9.5 &#xb1; 4.4 vs 4.3 &#xb1; 2.5(All P&lt;0.001)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B64">64</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">100% vs 100%</td>
<td valign="middle" align="left">10.3 vs 8.1(Median, P = 0.09)</td>
<td valign="middle" align="left">13.3 &#xb1; 8.9 vs 8.2 &#xb1; 6.5(P&lt;0.001)</td>
<td valign="middle" align="left">-(CRC&#x2019;s dedicated LN stratification is insufficient)</td>
<td valign="middle" align="left">Lesion count: 159 vs 47 (more with FAPI)</td>
<td valign="middle" align="left">TBR 8.1 vs 3.2(Median, P&lt;0.001)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B71">71</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">-(Exclusive to CRC)</td>
<td valign="middle" align="left">-(Exclusive to CRC)</td>
<td valign="middle" align="left">The TLR of all lesions was significantly higher.</td>
<td valign="middle" align="left">Lower gastrointestinal LN, 79% vs 54% (sensitivity)</td>
<td valign="middle" align="left">Higher (patient level)</td>
<td valign="middle" align="left">Peritoneal TLR 7.8 vs 1.9;TBR 4.9 vs 3.0</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B61">61</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">-(Merged analysis)</td>
<td valign="middle" align="left">-(Combined Analysis)</td>
<td valign="middle" align="left">-(Combined Analysis)</td>
<td valign="middle" align="left">78.6%/96.0%/92.2% vs 71.4%/70.0%/70.3%(Acc P = 0.002)</td>
<td valign="middle" align="left">-(Individual CRC)</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B53">53</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">In the recurrence scenario, FAPI is higher</td>
<td valign="middle" align="left">-(Original SUV)</td>
<td valign="middle" align="left">-(Primary TBR)</td>
<td valign="middle" align="left">-(quantitative)</td>
<td valign="middle" align="left">FAPI is more sensitive, PCI is higher, and AUC is higher.</td>
<td valign="middle" align="left">The peritoneum has higher contrast (qualitative)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B67">67</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">-(Single column)</td>
<td valign="middle" align="left">-(Single column)</td>
<td valign="middle" align="left">The overall FAPI is higher</td>
<td valign="middle" align="left">Overall sensitivity/accuracy, 98%/97% vs 78%/86%</td>
<td valign="middle" align="left">Sensitivity: 96% vs 66%</td>
<td valign="middle" align="left">Higher (qualitative)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B69">69</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Figure caption example:-:No data.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="s3_5">
<title>Peritoneum-dominant tumor</title>
<sec id="s3_5_1">
<title>Peritoneal cancer</title>
<p>Malignant peritoneal surface tumors typically present as diffuse small nodules and serosal dissemination; however, their early detection is challenged by minimal lesion volume, low metabolic activity characteristic of mucinous and signet-ring cell subtypes, and physiological intestinal uptake of tracers (<xref ref-type="bibr" rid="B72">72</xref>, <xref ref-type="bibr" rid="B73">73</xref>). By selectively targeting fibroblast activation protein (FAP)-expressing tumor stroma&#x2014;commonly rich in CAFs and characterized by low physiological bowel uptake&#x2014;FAPI PET/CT yields superior lesion-to-background contrast compared to <sup>18</sup>F-FDG PET/CT, especially in mucinous and signet-ring cell carcinomas with low FDG avidity (<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B75">75</xref>). Evidence from a systematic review and meta-analysis (11 studies, 340 patients) confirms this benefit, demonstrating significantly higher pooled patient-level sensitivity for FAPI PET/CT compared with FDG PET/CT (98.2% vs 55.9%), along with a consistent advantage in lesion-level sensitivity (99.9% vs 27.3%) (<xref ref-type="bibr" rid="B74">74</xref>). In a paired single-center cohort (n=46), FAPI demonstrated superior sensitivity for detecting peritoneal carcinomatosis (97.67% vs 72.09%); notably, sensitivity in gastric cancer, including the signet-ring cell subtype, improved from 53.85% with FDG to 100% with FAPI, accompanied by a higher median lesion SUVmax (9.82 vs 3.48) and an elevated imaging-derived peritoneal cancer index (18 vs 6) (<xref ref-type="bibr" rid="B76">76</xref>). In a prospective paired-cohort study of 113 patients imaged within a two-week interval, FAPI imaging eliminated the need for fasting, utilized a lower administered activity of 0.3&#x2013;3.1 MBq/kg (compared with 2.8&#x2013;7.0 MBq/kg for FDG), and demonstrated a favorable safety profile with&#xa0;no adverse events reported. At the patient level, FAPI exhibited&#xa0;superior sensitivity, negative predictive value (NPV), and accuracy relative to FDG (100% vs. 93.2%, 100% vs. 22.22%, and 93.81% vs. 86.73%, respectively), whereas specificity and positive predictive value (PPV) were comparable between the two tracers (<xref ref-type="bibr" rid="B77">77</xref>). The&#xa0;minimal physiological intestinal uptake yields a high target-to-background ratio, which enhances the visualization of small nodules located on the mesentery, omentum, and pelvic&#xa0;peritoneal surfaces, thus enabling more accurate assessment of&#xa0;lesion burden and peritoneal carcinomatosis index (PCI)&#xa0;estimation (<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B75">75</xref>). In cases of malignant peritoneal mesothelioma, case-control studies reveal intense fibroblast activation protein inhibitor (FAPI) accumulation (with SUVmax values reaching approximately 20) in areas of peritoneal or omental thickening, even when fluorodeoxyglucose (FDG) uptake remains low to moderate&#x2014;suggesting a potential diagnostic utility for rare histological subtypes and limited disease burden (<xref ref-type="bibr" rid="B78">78</xref>). From a clinical perspective, accurate preoperative prediction of the Peritoneal Carcinomatosis Index (PCI) is critical for patient selection for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), as a PCI exceeding 20 often precludes the procedure. Enhancements in imaging sensitivity and tumor-to-background ratio (TBR) could improve the concordance between radiologically assessed PCI and surgical observations, potentially reducing the incidence of non-therapeutic laparotomies. However, prospective multicenter validation and the establishment of standardized image interpretation criteria are imperative (<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B75">75</xref>). Collectively, current evidence indicates that FAPI PET/CT offers superior detection and delineation of peritoneal tumor burden&#x2014;particularly in FDG-low mucinous and signet-ring cell carcinomas&#x2014;while forthcoming studies are warranted to further elucidate specificity, pitfalls associated with inflammation-related uptake, and standardization to support broader clinical adoption (<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>). Radar plots summarize the relative performance of FAPI PET/CT (red) versus <sup>18</sup>-FDG PET/CT (blue) across six key imaging metrics, including sensitivity, specificity, tumor-to-background ratio (TBR), SUVmax_\text{max}max&#x200b;, lesion detection rate, and staging accuracy, in eight representative cancer types: lung cancer, ovarian cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, colorectal cancer, and peritoneal malignancies. These radar plots are intended as a schematic visualization to highlight tumor-specific diagnostic profiles and complementary strengths of the two tracers, rather than to imply direct numerical comparability or statistical equivalence between metrics (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref>). Current evidence demonstrates that FAPI-PET/CT is superior to <sup>18</sup>F-FDG PET/CT in lesion contrast (TBR), diagnostic sensitivity, and accuracy of imaging-based peritoneal cancer index (PCI) assessment for peritoneal malignancies, particularly in low FDG-avid histological subtypes such as mucinous adenocarcinoma and signet ring cell carcinoma, where it provides enhanced detection capability and improved risk stratification. In clinical practice, patients are typically required to fast before <sup>18</sup>F-FDG PET/CT to minimize physiological glucose uptake in the gastrointestinal tract and ensure optimal image quality. In contrast, FAPI PET/CT generally does not necessitate fasting, offering greater patient convenience and improving adherence to the examination protocol.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>An evidence-weighted radar chart comparison of FAPI PET/CT and <sup>18</sup>-FDG PET/CT performance across eight major solid tumor types.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1751727-g002.tif">
<alt-text content-type="machine-generated">Radar charts compare FAPI PET/CT and FDG PET/CT across eight cancer types: lung, ovarian, breast, liver, pancreatic, gastric, colorectal, and peritoneal. Metrics include sensitivity, specificity, staging accuracy, lesion detection rate, TBR, and SUVmax. FAPI PET/CT is shown in red, and FDG PET/CT in blue.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_5_2">
<title>Other cancers</title>
<p>FAPI-PET/CT demonstrates superior performance in various solid tumors beyond lung, liver, pancreas, ovary, breast, stomach, colorectal, and primary peritoneal malignancies compared to <sup>18</sup>F-FDG-PET/CT (<xref ref-type="bibr" rid="B79">79</xref>).</p>
</sec>
<sec id="s3_5_3">
<title>Cholangiocarcinoma</title>
<p>Independent paired studies have consistently demonstrated that FAPI exhibits higher tumor-to-background ratios and greater peak SUV values compared to FDG within the same patient cohort, further substantiating its superior contrast characteristics and enhanced lesion visualization in biliary system tumors (<xref ref-type="bibr" rid="B80">80</xref>). Independent paired studies have consistently shown that FAPI achieves higher tumor-to-background ratios and greater peak SUV values compared to FDG in the same patient population, further supporting its enhanced contrast performance and improved lesion visualization in biliary system tumors (<xref ref-type="bibr" rid="B81">81</xref>).</p>
</sec>
<sec id="s3_5_4">
<title>Nasopharyngeal carcinoma</title>
<p>The lower physiological tracer uptake in the myocardium and liver resulted in enhanced tumor-to-background ratios (TBR) and improved interpretability of mediastinal and perihilar lesions, leading to increased staging accuracy and a reduced risk of false-positive interpretations. In a prospective study of nasopharyngeal carcinoma, FAPI-04 achieved a 100% detection rate for primary tumors, surpassing the 96% detection rate of FDG. Researchers highlighted that the low background activity of FAPI in the head and neck region facilitated clearer delineation of complex anatomical boundaries, thereby improving the accuracy of T staging and local invasion assessment (<xref ref-type="bibr" rid="B82">82</xref>).</p>
</sec>
<sec id="s3_5_5">
<title>Cervical cancer</title>
<p>Head-to-head data in cervical cancer show no SUVmax difference between FAPI and FDG for primary or metastatic lesions; however, FDG yields more false positives, whereas FAPI reduces misclassification, indicating higher specificity and more reliable lymph-node staging in inflammation-prone pelvic settings. In metabolically cold histologies (e.g., endometrial clear cell carcinoma), FDG uptake is frequently low, while FAPI demonstrates robust avidity in primary and disseminated disease, improving staging; collectively, FAP-targeted stromal imaging increases diagnostic sensitivity and tumor-to-background ratio (<xref ref-type="bibr" rid="B80">80</xref>). In addition, early clinical applications have demonstrated that FAPI enables TBR-based quantitative stratification and facilitates imaging-based staging without the need for anesthesia. This technical methodology and its associated quantitative framework lay the groundwork for future standardization efforts and seamless integration with radiotherapy planning protocols (<xref ref-type="bibr" rid="B83">83</xref>).</p>
</sec>
<sec id="s3_5_6">
<title>Bladder cancer</title>
<p>In a real-world matched cohort analysis of bladder cancer, FAPI demonstrated significantly higher tumor-to-blood pool TBR compared to FDG (P value= 0.001 for inter-lesion TBR comparisons among metastatic sites), and identified a greater number of metastatic lesions within the same patient (31 vs. 22 total lesions). This finding contrasts with the high background signal observed with FDG in the urinary tract, underscoring FAPI&#x2019;s combined advantages of elevated tracer uptake and reduced background activity. At the individual lesion level, FAPI exhibited significantly higher SUVmax values in hilar lymph nodes and intrapulmonary metastases compared to FDG within the same patients, further emphasizing its enhanced sensitivity for detecting nodules and nodular metastases during systemic staging of urinary tract malignancies (<xref ref-type="bibr" rid="B84">84</xref>).</p>
</sec>
<sec id="s3_5_7">
<title>Thyroid cancer</title>
<p>In the context of differentiated thyroid cancer, paired comparative analyses have shown that the diagnostic accuracy of <sup>18</sup>F-FAPI-42 is largely on par with that of FDG. However, FAPI exhibits higher tracer uptake and improved detection rates for local recurrences and lymph node metastases, particularly in FDG-negative lesions and complex anatomical regions, where its low background activity results in superior TBR. In control cases involving radioactive iodine-refractory (RAIR) disease, FAPI showed significantly reduced physiological uptake in high-background organs such as the brain, liver, and myocardium, thereby enhancing the visualization and contrast of small lesions&#x2014;including pulmonary micrometastases. These findings further support the complementary role of FAPI in &#x201c;FDG-cold&#x201d; and RAIR clinical scenarios (<xref ref-type="bibr" rid="B85">85</xref>).</p>
</sec>
<sec id="s3_5_8">
<title>Head and neck tonsillar carcinoma</title>
<p>Head-to-head evaluation of FAPI-PET/CT demonstrates maintained lesion-background contrast and improved lesion visualization despite the high physiological FDG uptake in the pharyngeal lymphoid ring. This performance aligns with the overall low background distribution of FAPI in the head and neck region and corroborates previous evidence from nasopharyngeal carcinoma (NPC) studies (<xref ref-type="bibr" rid="B86">86</xref>).</p>
</sec>
<sec id="s3_5_9">
<title>Multiple myeloma</title>
<p>In clinical studies of multiple myeloma, although no statistically significant overall difference in SUVmax was observed between FAPI and FDG for bone lesions, FAPI demonstrated higher SUVmax values in 6 out of 8 individual cases. Moreover, FAPI identified additional bone lesions and medullary cavity involvement in certain patients, features that were not captured by FDG. The potential for FDG to yield false-negative results has been previously reported in the literature. The low background signal associated with FAPI contributes to improved lesion visualization and more comprehensive assessment (<xref ref-type="bibr" rid="B87">87</xref>).</p>
</sec>
<sec id="s3_5_10">
<title>Lymphoma</title>
<p>FDG remains superior for overall staging and lesion detection. However, FAPI demonstrates added value in specific subregions such as the liver, central nervous system, and head and neck areas, where its low background activity and higher tumor-to-liver ratios (TLR) provide complementary diagnostic information. These findings suggest that FAPI and FDG offer complementary strengths in diverse biological phenotypes and anatomical contexts (<xref ref-type="bibr" rid="B88">88</xref>).</p>
</sec>
<sec id="s3_5_11">
<title>Dermatofibrosarcoma protuberan</title>
<p>FAPI provides superior visualization of lesion extent and deep tissue invasion compared to FDG, thereby expanding the boundaries of preoperative assessment and potentially influencing surgical planning. This diagnostic advantage aligns with FAPI&#x2019;s high uptake in tumors characterized by abundant fibrous stroma (<xref ref-type="bibr" rid="B89">89</xref>).</p>
</sec>
<sec id="s3_5_12">
<title>Epithelioid malignant pleural mesothelioma</title>
<p>FAPI demonstrates superior delineation of diffuse pleural lesions and lymph node involvement at the cardio-diaphragmatic angle compared to FDG. This highlights its advantages in accurately defining lesion boundaries and extent on the pleural surface, particularly in encapsulated (wrapped-type) or metabolically heterogeneous tumors (<xref ref-type="bibr" rid="B90">90</xref>).</p>
</sec>
<sec id="s3_5_13">
<title>Venous-type leiomyomatosi</title>
<p>A rare yet frequently misdiagnosed solid tumor, exhibits significantly higher uptake of FAPI compared to FDG (as exemplified by SUVmax values of 9.9 vs. 2.0). This indicates FAPI&#x2019;s strong affinity for lesions composed of smooth muscle and abundant fibrous stroma, offering enhanced capability in tracing systemic metastatic pathways and facilitating more accurate preoperative risk assessment (<xref ref-type="bibr" rid="B91">91</xref>&#x2013;<xref ref-type="bibr" rid="B93">93</xref>). However, FAPI is not universally applicable. It also demonstrates sensitivity to fibro-inflammatory processes. Previous studies have reported co-uptake of FAPI and FDG in conditions such as elastofibroma, as well as in spinal and cardiac tuberculosis, which poses challenges to diagnostic specificity. These findings underscore the importance of integrating morphological features, clinical follow-up, and histopathological evidence during image interpretation to prevent over-staging (<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B94">94</xref>).</p>
<p>To systematically present the comparative performance of FAPI and <sup>18</sup>F-FDG across key parameters in other cancers, this article summarizes and synthesizes the available research data (<xref ref-type="table" rid="T5"><bold>Table&#xa0;5</bold></xref>). FAPI PET/CT demonstrates a consistent overall advantage across solid tumors in tumor-to-background ratio, lesion detection rate, and staging accuracy when compared with <sup>18</sup>-FDG PET/CT. These trends are particularly driven by tumor types characterized by abundant stromal reaction or low glycolytic activity.In contrast, the specificity of FAPI PET/CT appears more variable across tumor types, reflecting its known sensitivity to fibro-inflammatory processes, whereas <sup>18</sup>-FDG PET/CT maintains relatively stable specificity in selected clinical contexts. Notably, SUVmax shows overall comparable performance between the two tracers, underscoring their complementary biological targets.This schematic summary should be interpreted as an integrative visualization of evidence trends rather than a quantitative comparison (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3</bold></xref>). The core value of FAPI-PET/CT lies in its role as a complementary rather than replacement imaging modality. It effectively addresses the diagnostic limitations of FDG in tumors with low metabolic activity, regions with high physiological background uptake, and small lesion foci, thereby expanding the armamentarium of clinical imaging tools. However, current evidence is largely derived from single-center or small-sample studies. Future multicenter, prospective trials are essential to establish standardized SUV/TBR threshold criteria and define tumor subtype-specific &#x201c;application guidelines&#x201d; Such efforts will facilitate the accurate integration of FAPI-PET/CT into clinical diagnostic and therapeutic pathways, ultimately enabling the translation of its technical advantages into tangible patient benefits.</p>
<table-wrap id="T5" position="float">
<label>Table&#xa0;5</label>
<caption>
<p>Summary of key parameter comparisons (FAPI vs FDG, Other Cancers).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Cancer type</th>
<th valign="middle" align="left">Indicators/Scenarios</th>
<th valign="middle" align="left">Evaluation level</th>
<th valign="middle" align="left">FAPI</th>
<th valign="middle" align="left">FDG</th>
<th valign="middle" align="left">Note</th>
<th valign="middle" align="left">References</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Biliary tract tumors</td>
<td valign="middle" align="left">Detection rate of primary lesion</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">100%</td>
<td valign="middle" align="left">81%</td>
<td valign="middle" align="left">16/16 vs 13/16</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B79">79</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Biliary tract tumors</td>
<td valign="middle" align="left">Detection rate of lymph nodes</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">98%</td>
<td valign="middle" align="left">83%</td>
<td valign="middle" align="left">41/42 vs 35/42</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B79">79</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Biliary tract tumors</td>
<td valign="middle" align="left">Detection rate of distant metastasis</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">100%</td>
<td valign="middle" align="left">79%</td>
<td valign="middle" align="left">99/99 vs 78/99</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B79">79</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Esophageal cancer</td>
<td valign="middle" align="left">Lymph node sensitivity</td>
<td valign="middle" align="left">regional level</td>
<td valign="middle" align="left">95.00%</td>
<td valign="middle" align="left">75.00%</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B95">95</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Esophageal cancer</td>
<td valign="middle" align="left">Lymph node specificity</td>
<td valign="middle" align="left">regional level</td>
<td valign="middle" align="left">98.40%</td>
<td valign="middle" align="left">77.20%</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B95">95</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Esophageal cancer</td>
<td valign="middle" align="left">Accuracy of lymph nodes</td>
<td valign="middle" align="left">regional level</td>
<td valign="middle" align="left">97.30%</td>
<td valign="middle" align="left">76.40%</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B95">95</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Esophageal cancer</td>
<td valign="middle" align="left">The mean &#xb1; SD of SUVmax of lymph nodes</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">9.3 &#xb1; 5.2</td>
<td valign="middle" align="left">6.4 &#xb1; 5.9</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B95">95</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Nasopharyngeal carcinoma</td>
<td valign="middle" align="left">Detection rate of primary lesion</td>
<td valign="middle" align="left">Patient level</td>
<td valign="middle" align="left">100%</td>
<td valign="middle" align="left">96%</td>
<td valign="middle" align="left">28/28 vs 27/28</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B82">82</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Nasopharyngeal carcinoma</td>
<td valign="middle" align="left">False positive lymph nodes</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">51</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B82">82</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Nasopharyngeal carcinoma</td>
<td valign="middle" align="left">False positive lymph nodes</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">20</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B82">82</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Nasopharyngeal carcinoma</td>
<td valign="middle" align="left">The mean &#xb1; SD of SUVmax of lymph nodes</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">11.7 &#xb1; 5.0</td>
<td valign="middle" align="left">13.6 &#xb1; 5.5</td>
<td valign="middle" align="left">There was no statistically significant difference</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B82">82</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Cervical cancer</td>
<td valign="middle" align="left">Detection rate of primary lesion</td>
<td valign="middle" align="left">Patient level</td>
<td valign="middle" align="left">100%</td>
<td valign="middle" align="left">100%</td>
<td valign="middle" align="left">All 35 were detected.</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B81">81</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Cervical cancer</td>
<td valign="middle" align="left">Detection rate of lymph nodes</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">100%</td>
<td valign="middle" align="left">98%</td>
<td valign="middle" align="left">50/50 vs 49/50</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B81">81</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Cervical cancer</td>
<td valign="middle" align="left">False positive lymph nodes</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B81">81</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Cervical cancer</td>
<td valign="middle" align="left">The mean &#xb1; SD of SUVmax of lymph nodes</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">7.0 &#xb1; 3.5</td>
<td valign="middle" align="left">7.6 &#xb1; 4.0</td>
<td valign="middle" align="left">The difference was not significant</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B81">81</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Tonsillar cancer</td>
<td valign="middle" align="left">SUVmax of the primary lesion (mean &#xb1; SD)</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">5.03 &#xb1; 4.06</td>
<td valign="middle" align="left">7.90 &#xb1; 4.84</td>
<td valign="middle" align="left">Higher FDG</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B89">89</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Tonsillar cancer</td>
<td valign="middle" align="left">Primary lesion TBR (mean &#xb1; SD)</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">3.19 &#xb1; 2.06</td>
<td valign="middle" align="left">1.87 &#xb1; 1.80</td>
<td valign="middle" align="left">FAPI was significantly higher.(p&lt;0.001)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B89">89</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Tonsillar cancer</td>
<td valign="middle" align="left">Sensitivity of cervical lymph nodes</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">87.23%</td>
<td valign="middle" align="left">95.74%</td>
<td valign="middle" align="left">The difference was not significant(p=0.125)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B89">89</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Tonsillar cancer</td>
<td valign="middle" align="left">Cervical lymph node specificity</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">46.15%</td>
<td valign="middle" align="left">11.54%</td>
<td valign="middle" align="left">FAPI was significantly higher.(p=0.004)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B89">89</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Tonsillar cancer</td>
<td valign="middle" align="left">Accuracy of cervical lymph nodes</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">72.60%</td>
<td valign="middle" align="left">65.75%</td>
<td valign="middle" align="left">FAPI was significantly higher.(p&lt;0.001)</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B89">89</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Bladder cancer</td>
<td valign="middle" align="left">TBR (tumor/blood pool) of metastatic lesion</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">5.33</td>
<td valign="middle" align="left">1.95</td>
<td valign="middle" align="left">p=0.001</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B84">84</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Differentiated thyroid carcinoma</td>
<td valign="middle" align="left">Sensitivity (patient level)</td>
<td valign="middle" align="left">Patient level</td>
<td valign="middle" align="left">82.80%</td>
<td valign="middle" align="left">96.60%</td>
<td valign="middle" align="left">Higher FDG</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B85">85</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Differentiated thyroid carcinoma</td>
<td valign="middle" align="left">Sensitivity (lesion level)</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">69.80%</td>
<td valign="middle" align="left">88.60%</td>
<td valign="middle" align="left">Higher FDG</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B85">85</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">Differentiated thyroid carcinoma</td>
<td valign="middle" align="left">Positive predictive value (PPV)</td>
<td valign="middle" align="left">Lesion level</td>
<td valign="middle" align="left">73.70%</td>
<td valign="middle" align="left">89.20%</td>
<td valign="middle" align="left">Higher FDG</td>
<td valign="middle" align="left">(<xref ref-type="bibr" rid="B85">85</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Figure caption example:-:No data.</p></fn>
</table-wrap-foot>
</table-wrap>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Schematic radar plot summarizing overall performance trends of FAPI PET/CT versus <sup>18</sup>-FDG PET/CT across solid tumors.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1751727-g003.tif">
<alt-text content-type="machine-generated">Radar chart comparing FAPI PET/CT and FDG PET/CT across five metrics: sensitivity, specificity, TBR, SUVmax, lesion detection rate, and staging accuracy. FAPI PET/CT is represented in red, while FDG PET/CT is in blue. Each axis is labeled with values from 0.40 to 1.00. FAPI PET/CT shows higher values in certain metrics than FDG PET/CT, as indicated by the shaded areas.</alt-text>
</graphic></fig>
</sec>
</sec>
</sec>
<sec id="s4">
<title>Current challenges and prospects for future development</title>
<p>FAP is highly expressed on CAFs in most epithelial malignancies, offering a stromal-targeted imaging target that is distinct from glucose metabolism and contributing to the rapid adoption of FAPI PET/CT as a complementary&#x2014;rather than a complete substitute for&#x2014;<sup>18</sup>F-FDG PET/CT (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B96">96</xref>). FAPI imaging capitalizes on the widespread presence and functional contributions of CAFs in tumor invasion, immune modulation, and extracellular matrix remodeling, thereby enhancing lesion visibility even in cases where tumor cell glycolysis is limited (<xref ref-type="bibr" rid="B18">18</xref>). Clinical reviews summarize the extensive early experience across various tumor types, highlighting both the potential of FAPI PET/CT and the necessity for standardization (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B97">97</xref>).</p>
<p>Technically, FAPI tracers frequently achieve higher tumor-to-background ratios compared to FDG, owing to their low physiological uptake in many normal organs, which enhances lesion detectability in the abdomen and central nervous system (CNS) (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B98">98</xref>). Early human data with <sup>18</sup>F-FAPI-42 suggest a relatively flexible acquisition window (approximately 60&#x2013;120 minutes post-injection), characterized by high tumor uptake and generally low standardized uptake values (SUVs) in normal organs, thereby facilitating adaptable imaging workflows (<xref ref-type="bibr" rid="B99">99</xref>).</p>
<p>Radiochemistry innovations, such as FAPI-74&#x2014;which is available as either a <sup>68</sup>Ga kit or <sup>18</sup>F-AlF formulation&#x2014;expand accessibility while maintaining favorable dosimetry profiles (<xref ref-type="bibr" rid="B14">14</xref>). In parallel, <sup>18</sup>F-labeled peptides (e.g., <sup>18</sup>F-FAP-2286 and <sup>18</sup>F-AlF-FAP-NUR) demonstrate excellent image quality and offer the advantage of not requiring strict dietary or fasting protocols, thereby facilitating their integration into routine clinical practice (<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B100">100</xref>).</p>
<p>Head-to-head evidence indicates context-dependent performance: in mixed-cancer cohorts, FAPI frequently achieves higher target-to-background ratios with comparable or superior lesion detection compared to FDG, although results may vary by anatomical site and histological subtype (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B96">96</xref>). In liver metastases <sup>68</sup>Ga-FAPI detects more lesions than FDG and achieves significantly higher tumor-to-background ratios (TBR), despite occasionally lower absolute lesion SUVmax values, thereby substantially improving lesion conspicuity (<xref ref-type="bibr" rid="B101">101</xref>). Meta-analytic synthesis suggests that FAPI outperforms FDG in the detection of nodal metastases, yet demonstrates no significant advantage in the assessment of osseous disease, thereby highlighting its domain-specific diagnostic strengths (<xref ref-type="bibr" rid="B102">102</xref>). Disease-specific studies, such as those focused on cholangiocarcinoma, consistently report superior staging performance with FAPI-based imaging compared to FDG and/or CT (<xref ref-type="bibr" rid="B80">80</xref>). Prospective studies directly comparing FAPI with FDG for tumor staging are currently underway, reflecting a transition from feasibility assessment to evaluations of clinical decision impact (<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B97">97</xref>).</p>
<p>Biologically, FAPI PET visualizes the tumor microenvironment rather than tumor glycolysis, a mechanistic distinction that enhances sensitivity in desmoplastic cancers while also rendering the modality susceptible to fibroblast-rich benign processes. A systematic review has cataloged numerous non-malignant FAPI-avid conditions&#x2014;including post-surgical scars, fibrotic or inflammatory lesions, and arthritis&#x2014;that require clinicoradiologic correlation to prevent over-staging. For example, pancreatitis may&#xa0;exhibit FAPI uptake resembling that of pancreatic cancer, although careful PET/MR evaluation can assist in differentiation. Tuberculosis (including cardiac involvement) can demonstrate avidity for both FDG and FAPI, underscoring the importance of pathologic or microbiologic confirmation in endemic regions (<xref ref-type="bibr" rid="B18">18</xref>). Renal findings observed with FAPI imaging&#x2014;such as cortical signal accumulation in cases of acute kidney injury&#x2014;highlight how FAP expression during tissue remodeling can generate biologically plausible confounders that pose diagnostic challenges (<xref ref-type="bibr" rid="B97">97</xref>, <xref ref-type="bibr" rid="B103">103</xref>).</p>
<p>A promising near-term strategy involves purposeful dual-tracer imaging, which integrates complementary metabolic signals from tumor cells and stromal components to reduce false-negative results and improve tumor phenotyping (<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B102">102</xref>). Single-session FDG+FAPI protocols are feasible and have shown clinically meaningful improvements in staging precision; in esophageal cancer, dual-tracer imaging has influenced radiotherapy target delineation and dose planning decisions (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B102">102</xref>). Combining PET with MRI takes advantage of MRI&#x2019;s excellent soft-tissue contrast to improve radiation treatment planning and evaluation of therapeutic response, especially in the pelvic and head-and-neck area (<xref ref-type="bibr" rid="B98">98</xref>,&#xa0;<xref ref-type="bibr" rid="B104">104</xref>). Total-body systems can capture whole-organism kinetic data from both tracers, potentially enabling parametric mapping and microdosimetry approaches that correlate imaging phenotypes with clinical outcomes (<xref ref-type="bibr" rid="B98">98</xref>).</p>
<p>Theranostics represents another promising frontier: FAPI-based radioligand therapy has entered first-in-human trials (e.g.,&#xa0;90Y/177Lu-FAPI-46), and peptide-based agents such as FAP-2286 provide a genuine imaging-to-therapy continuum (<xref ref-type="bibr" rid="B91">91</xref>,&#xa0;<xref ref-type="bibr" rid="B105">105</xref>). Novel&#xa0;chemotypes (e.g., heterobivalent <sup>68</sup>Ga-FAPI-LM3) aim to achieve stronger binding affinity and enhanced retention, whereas <sup>18</sup>F-labeling strategies (e.g., <sup>18</sup>F-FAP-2286, <sup>18</sup>F-AlF-FAP-NUR) are designed to support mass production and logistical scalability, facilitating broader clinical adoption (<xref ref-type="bibr" rid="B100">100</xref>). Forward-looking trials should correlate imaging phenotypes&#x2014;such as stromal density, nodal versus osseous tropism, and kinetic parameters&#x2014;with patient-level endpoints, and evaluate how dual-tracer or multimodal imaging strategies influence decisions regarding surgery, radiotherapy, or systemic therapy (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B96">96</xref>).</p>
<p>In summary, FAPI PET/CT complements <sup>18</sup>F-FDG by visualizing the stromal component with high contrast and through practical imaging workflows. However, Current barriers to the cost-effectiveness evaluation of FAPI PET/CT include limited large-scale commercial availability of radiotracers, inconsistent production processes and regulatory approvals, substantial heterogeneity among FAPI variants and imaging protocols without established standardization, a scarcity of prospective multicenter cost-effectiveness studies, and an unquantified incremental benefit for clinical decision-making and patient outcomes.the occurrence of biologically plausible false positives and variable performance across different anatomical sites necessitates its careful integration with clinical context, adherence to standardized protocols, and, in many clinical settings, the deliberate use of dual-tracer or multimodal imaging strategies to optimize individualized oncologic care.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusion</title>
<p>FAPI PET/CT has rapidly evolved into a clinically valuable complementary tool&#x2014;as opposed to a direct replacement&#x2014;to <sup>18</sup>F-FDG, supported by head-to-head comparisons and meta-analytic evidence, and is now formally recognized by the first joint SNMMI/EANM practice guideline for FAP PET (<xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B107">107</xref>). In the short term, FAPI&#x2019;s consistently low physiological background activity in key organs (e.g., brain, liver, oral mucosa) results in high tumor-to-background ratios and lesion conspicuity, thereby facilitating accurate staging and target delineation in scenarios where FDG may be limited by variable normal tissue uptake (<xref ref-type="bibr" rid="B106">106</xref>). Optimized protocols (e.g., early post-injection imaging windows) further streamline workflow and may improve lesion detection, while maintaining favorable biodistribution and dosimetric profiles across FAPI-targeted agents (<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B108">108</xref>). Pooled head-to-head analyses demonstrate that FAPI enhances the detection of lymph node metastases across a range of cancer types, with performance for bone metastases being broadly comparable to that of FDG. These findings support the near-term implementation of FAPI PET/CT for nodal mapping and comprehensive cancer staging (<xref ref-type="bibr" rid="B102">102</xref>). In parallel, same-session dual-tracer protocols (FDG + FAPI) are technically feasible and demonstrate superior performance compared to single-tracer imaging, enabling comprehensive whole-patient phenotyping by integrating information on glycolysis and stromal activation (<xref ref-type="bibr" rid="B109">109</xref>). The biological rationale for FAPI imaging is robust, CAF-rich tumor stroma abundantly expresses FAP, allowing visualization of a microenvironmental hallmark that is distinct from tumor glucose metabolism and thus complementary to FDG (<xref ref-type="bibr" rid="B110">110</xref>). Nevertheless, short-term clinical implementation must account for well-documented limitations&#x2014;FAPI uptake in non-malignant fibroinflammatory conditions (e.g., degenerative bone or joint disease, fibrosis, post-surgical scars, pancreatitis, granulomatous infections) may decrease diagnostic specificity and necessitates careful clinicoradiologic correlation (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B97">97</xref>, <xref ref-type="bibr" rid="B111">111</xref>). Looking to the long term, the integration of FDG and FAPI into unified, indication-specific imaging algorithms&#x2014;including single-session dual-tracer protocols&#x2014;holds promise for enhanced phenotyping to guide response-adaptive therapy, surgical or radiotherapy planning, and the earlier detection of micrometastatic disease (<xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B109">109</xref>).</p>
<p>To provide a concise and practice-focused overview, we have consolidated the comparative evidence&#x2014;organized by disease category, research model, and principal experimental conditions&#x2014;into a synthesized evidence map (<xref ref-type="table" rid="T6"><bold>Table&#xa0;6</bold></xref>). This table highlights the domains in which FAPI PET/CT exhibits the most consistent added value compared to <sup>18</sup>F-FDG PET/CT. Current evidence highlights heterogeneity across tumor types and study designs, emphasizing the need for large-scale, prospective, tumor-specific clinical trials that utilize harmonized protocols and quantitative endpoints (<xref ref-type="bibr" rid="B102">102</xref>). The near-term value of FAPI PET/CT lies in its ability to improve lesion conspicuity, enhance nodal assessment accuracy, and provide actionable dual-tracer synergy. In the long term, its potential resides in the development of standardized, biology-informed imaging pathways that integrate stromal and metabolic biomarkers to enable personalized cancer care.</p>
<table-wrap id="T6" position="float">
<label>Table&#xa0;6</label>
<caption>
<p>This review provides a summary, organized by disease type, model, and imaging conditions, of the comparative performance between FAPI PET and <sup>18</sup>F-FDG PET.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Disease</th>
<th valign="middle" align="left">Evidence model</th>
<th valign="middle" align="left">Key imaging conditions</th>
<th valign="middle" align="left">Main conclusions vs FDG</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Lung cancer</td>
<td valign="middle" align="left">Prospective real-world + meta-analysis</td>
<td valign="middle" align="left">~1 h p.i.</td>
<td valign="middle" align="left">Improved N/M staging; higher TBR (brain/bone); management impact</td>
</tr>
<tr>
<td valign="middle" align="left">Hepatocellular carcinoma</td>
<td valign="middle" align="left">Prospective + retrospective head-to-head</td>
<td valign="middle" align="left">Fibrosis/steatosis may increase background</td>
<td valign="middle" align="left">Superior initial staging, recurrence detection, and small lesion visualization</td>
</tr>
<tr>
<td valign="middle" align="left">Ovarian cancer</td>
<td valign="middle" align="left">Prospective H2H + retrospective + systematic evidence</td>
<td valign="middle" align="left">PET/MR for upper abdomen/diaphragm; PCI-based</td>
<td valign="middle" align="left">Advantages in peritoneal disease and small LN; greater impact in recurrence/platinum-sensitive settings</td>
</tr>
<tr>
<td valign="middle" align="left">Breast cancer</td>
<td valign="middle" align="left">Prospective H2H + paired analysis</td>
<td valign="middle" align="left">No special preparation</td>
<td valign="middle" align="left">Superior axillary staging; advantages in low-FDG subtypes and brain/bone/liver metastases</td>
</tr>
<tr>
<td valign="middle" align="left">PDAC</td>
<td valign="middle" align="left">Prospective H2H + pooled evidence (7 studies/322 pts)</td>
<td valign="middle" align="left">18F-AIF-FAPI-74 with low background</td>
<td valign="middle" align="left">Improved whole-course staging and small lesion detection; future need for multicenter standardization and FDG complementarity</td>
</tr>
<tr>
<td valign="middle" align="left">Gastric cancer</td>
<td valign="middle" align="left">Prospective H2H + PET/MR + reviews</td>
<td valign="middle" align="left">&#x2265;52% decline in SUVmax/TBR predicts MPR</td>
<td valign="middle" align="left">Superior in FDG-low subtypes and peritoneal metastasis; potential for early response assessment</td>
</tr>
<tr>
<td valign="middle" align="left">Colorectal cancer</td>
<td valign="middle" align="left">Multiple H2H + meta-analysis</td>
<td valign="middle" align="left">Low peritoneal/bowel background benefits PCI</td>
<td valign="middle" align="left">Enhanced LN, peritoneal (PCI), and small liver metastasis detection; frequent TNM upstaging</td>
</tr>
<tr>
<td valign="middle" align="left">Peritoneal tumors/metastasis</td>
<td valign="middle" align="left">Meta-analysis (11 studies/340 pts) + prospective pairs</td>
<td valign="middle" align="left">No fasting; 0.3&#x2013;3.1 MBq/kg</td>
<td valign="middle" align="left">High impact on PCI assessment and clinical decision-making; VOI/PCI standardization needed</td>
</tr>
<tr>
<td valign="middle" align="left">Cholangiocarcinoma/BTC</td>
<td valign="middle" align="left">Multiple comparative studies</td>
<td valign="middle" align="left">Not specified</td>
<td valign="middle" align="left">Improved lesion conspicuity; prospective stage&#x2013;outcome validation required</td>
</tr>
<tr>
<td valign="middle" align="left">Esophageal cancer</td>
<td valign="middle" align="left">Prospective H2H</td>
<td valign="middle" align="left">Not specified</td>
<td valign="middle" align="left">Reduced overstaging; suitable for RT target delineation and micrometastasis monitoring</td>
</tr>
<tr>
<td valign="middle" align="left">Nasopharyngeal carcinoma</td>
<td valign="middle" align="left">Prospective</td>
<td valign="middle" align="left">Low head&#x2013;neck background</td>
<td valign="middle" align="left">Improved T-stage and invasion assessment; applicable to RT planning and surveillance</td>
</tr>
<tr>
<td valign="middle" align="left">Cervical cancer/metabolic-cold gynecologic tumors</td>
<td valign="middle" align="left">Head-to-head studies</td>
<td valign="middle" align="left">Not specified</td>
<td valign="middle" align="left">Increased specificity; improved staging of FDG-low subtypes; threshold standardization warranted</td>
</tr>
<tr>
<td valign="middle" align="left">Bladder cancer</td>
<td valign="middle" align="left">Matched-pair real-world analysis</td>
<td valign="middle" align="left">Not specified</td>
<td valign="middle" align="left">Overcomes FDG urinary interference; favorable for systemic staging and micrometastasis detection</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</body>
<back>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>YY: Writing &#x2013; original draft. JWZ: Writing &#x2013; original draft. JX: Writing &#x2013; original draft. CY: Writing &#x2013; original draft. XG: Writing &#x2013; original draft. JYZ: Writing &#x2013; original draft. PW: Writing &#x2013; original draft. LL: Writing &#x2013; review &amp; editing. JZZ: Writing &#x2013; review &amp; editing. JY: Data curation, Writing &#x2013; review &amp; editing. CC: Writing &#x2013; original draft. JJ: Writing &#x2013; review &amp; editing, Funding acquisition. BG: Supervision, Writing &#x2013; review &amp; editing, Software.</p></sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s9" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If&#xa0;you identify any issues, please contact us.</p></sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Blodgett</surname> <given-names>TM</given-names></name>
<name><surname>Meltzer</surname> <given-names>CC</given-names></name>
<name><surname>Townsend</surname> <given-names>DW</given-names></name>
</person-group>. 
<article-title>PET/CT: form and function</article-title>. <source>Radiology</source>. (<year>2007</year>) <volume>242</volume>:<page-range>360&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.2422051113</pub-id>, PMID: <pub-id pub-id-type="pmid">17255408</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Portnow</surname> <given-names>LH</given-names></name>
<name><surname>Vaillancourt</surname> <given-names>DE</given-names></name>
<name><surname>Okun</surname> <given-names>MS</given-names></name>
</person-group>. 
<article-title>The history of cerebral PET scanning</article-title>. <source>Neurology</source>. (<year>2013</year>) <volume>80</volume>:<page-range>952&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1212/WNL.0b013e318285c135</pub-id>, PMID: <pub-id pub-id-type="pmid">23460618</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kung</surname> <given-names>BT</given-names></name>
<name><surname>Mehdizadeh Seraj</surname> <given-names>S</given-names></name>
<name><surname>Zirakchian Zadeh</surname> <given-names>M</given-names></name>
<name><surname>Rojulpote</surname> <given-names>C</given-names></name>
<name><surname>Kothekar</surname> <given-names>E</given-names></name>
<name><surname>Ayubcha</surname> <given-names>C</given-names></name>
<etal/>
</person-group>. 
<article-title>An update on the role of 18F-FDG-PET/CT in major infectious and inflammatory diseases</article-title>. <source>Am J Nucl Med Mol Imaging</source>. (<year>2019</year>) <volume>9</volume>:<page-range>255&#x2013;73</page-range>., PMID: <pub-id pub-id-type="pmid">31976156</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Feng</surname> <given-names>H</given-names></name>
<name><surname>Wang</surname> <given-names>X</given-names></name>
<name><surname>Chen</surname> <given-names>J</given-names></name>
<name><surname>Cui</surname> <given-names>J</given-names></name>
<name><surname>Gao</surname> <given-names>T</given-names></name>
<name><surname>Gao</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>Nuclear imaging of glucose metabolism: Beyond<sup>18</sup> F-FDG</article-title>. <source>Contrast Media Mol Imaging</source>. (<year>2019</year>) <volume>2019</volume>:<fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/7954854</pub-id>, PMID: <pub-id pub-id-type="pmid">31049045</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lau</surname> <given-names>J</given-names></name>
<name><surname>Rousseau</surname> <given-names>E</given-names></name>
<name><surname>Kwon</surname> <given-names>D</given-names></name>
<name><surname>Lin</surname> <given-names>KS</given-names></name>
<name><surname>B&#xe9;nard</surname> <given-names>F</given-names></name>
<name><surname>Chen</surname> <given-names>X</given-names></name>
</person-group>. 
<article-title>Insight into the development of PET radiopharmaceuticals for oncology</article-title>. <source>Cancers</source>. (<year>2020</year>) <volume>12</volume>:<elocation-id>1312</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers12051312</pub-id>, PMID: <pub-id pub-id-type="pmid">32455729</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hess</surname> <given-names>S</given-names></name>
<name><surname>H&#xf8;ilund-Carlsen</surname> <given-names>PF</given-names></name>
<name><surname>Alavi</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>Historic images in nuclear medicine: 1976: the first issue of clinical nuclear medicine and the first human FDG study</article-title>. <source>Clin Nucl Med</source>. (<year>2014</year>) <volume>39</volume>:<page-range>701&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000000487</pub-id>, PMID: <pub-id pub-id-type="pmid">24978339</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pijl</surname> <given-names>JP</given-names></name>
<name><surname>Nienhuis</surname> <given-names>PH</given-names></name>
<name><surname>Kwee</surname> <given-names>TC</given-names></name>
<name><surname>Glaudemans</surname> <given-names>AWJM</given-names></name>
<name><surname>Slart</surname> <given-names>RHJA</given-names></name>
<name><surname>Gormsen</surname> <given-names>LC</given-names></name>
</person-group>. 
<article-title>Limitations and pitfalls of FDG-PET/CT in infection and inflammation</article-title>. <source>Semin Nucl Med</source>. (<year>2021</year>) <volume>51</volume>:<page-range>633&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1053/j.semnuclmed.2021.06.008</pub-id>, PMID: <pub-id pub-id-type="pmid">34246448</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tania Rahman</surname> <given-names>W</given-names></name>
<name><surname>Wale</surname> <given-names>DJ</given-names></name>
<name><surname>Viglianti</surname> <given-names>BL</given-names></name>
<name><surname>Townsend</surname> <given-names>DM</given-names></name>
<name><surname>Manganaro</surname> <given-names>MS</given-names></name>
<name><surname>Gross</surname> <given-names>MD</given-names></name>
<etal/>
</person-group>. 
<article-title>The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging</article-title>. <source>BioMed Pharmacother Biomed Pharmacother</source>. (<year>2019</year>) <volume>117</volume>:<elocation-id>109168</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2019.109168</pub-id>, PMID: <pub-id pub-id-type="pmid">31334700</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chandekar</surname> <given-names>KR</given-names></name>
<name><surname>Prashanth</surname> <given-names>A</given-names></name>
<name><surname>Vinjamuri</surname> <given-names>S</given-names></name>
<name><surname>Kumar</surname> <given-names>R</given-names></name>
</person-group>. 
<article-title>FAPI PET/CT imaging-an updated review</article-title>. <source>Diagn Basel Switz</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>2018</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/diagnostics13122018</pub-id>, PMID: <pub-id pub-id-type="pmid">37370912</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fitzgerald</surname> <given-names>AA</given-names></name>
<name><surname>Weiner</surname> <given-names>LM</given-names></name>
</person-group>. 
<article-title>The role of fibroblast activation protein in health and Malignancy</article-title>. <source>Cancer Metastasis Rev</source>. (<year>2020</year>) <volume>39</volume>:<fpage>783</fpage>&#x2013;<lpage>803</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10555-020-09909-3</pub-id>, PMID: <pub-id pub-id-type="pmid">32601975</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xin</surname> <given-names>L</given-names></name>
<name><surname>Gao</surname> <given-names>J</given-names></name>
<name><surname>Zheng</surname> <given-names>Z</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
<name><surname>Lv</surname> <given-names>S</given-names></name>
<name><surname>Zhao</surname> <given-names>Z</given-names></name>
<etal/>
</person-group>. 
<article-title>Fibroblast activation protein-&#x3b1; as a target in the bench-to-bedside diagnosis and treatment of tumors: A narrative review</article-title>. <source>Front Oncol</source>. (<year>2021</year>) <volume>11</volume>:<elocation-id>648187</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2021.648187</pub-id>, PMID: <pub-id pub-id-type="pmid">34490078</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bentestuen</surname> <given-names>M</given-names></name>
<name><surname>Ladekarl</surname> <given-names>M</given-names></name>
<name><surname>Knudsen</surname> <given-names>A</given-names></name>
<name><surname>Zacho</surname> <given-names>HD</given-names></name>
</person-group>. 
<article-title>Diagnostic accuracy and clinical value of [68Ga]ga-FAPI-46 PET/CT for staging patients with ovarian cancer: Study protocol for a prospective clinical trial</article-title>. <source>BMC Cancer</source>. (<year>2024</year>) <volume>24</volume>:<fpage>699</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12885-024-12461-w</pub-id>, PMID: <pub-id pub-id-type="pmid">38849741</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname> <given-names>R</given-names></name>
<name><surname>Pu</surname> <given-names>Y</given-names></name>
<name><surname>Huang</surname> <given-names>S</given-names></name>
<name><surname>Yang</surname> <given-names>C</given-names></name>
<name><surname>Yang</surname> <given-names>F</given-names></name>
<name><surname>Pu</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>FAPI-PET/CT in cancer imaging: A potential novel molecule of the century</article-title>. <source>Front Oncol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>854658</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.854658</pub-id>, PMID: <pub-id pub-id-type="pmid">35692767</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mori</surname> <given-names>Y</given-names></name>
<name><surname>Novruzov</surname> <given-names>E</given-names></name>
<name><surname>Schmitt</surname> <given-names>D</given-names></name>
<name><surname>Cardinale</surname> <given-names>J</given-names></name>
<name><surname>Watabe</surname> <given-names>T</given-names></name>
<name><surname>Choyke</surname> <given-names>PL</given-names></name>
<etal/>
</person-group>. 
<article-title>Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)</article-title>. <source>NPJ Imaging</source>. (<year>2024</year>) <volume>2</volume>:<fpage>48</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s44303-024-00053-z</pub-id>, PMID: <pub-id pub-id-type="pmid">40604259</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jacobson</surname> <given-names>FL</given-names></name>
<name><surname>Van den Abbeele</surname> <given-names>AD</given-names></name>
</person-group>. 
<article-title>Importance of 68Ga-FAPI PET/CT for detection of cancer</article-title>. <source>Radiology</source>. (<year>2022</year>) <volume>303</volume>:<page-range>200&#x2013;1</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.212884</pub-id>, PMID: <pub-id pub-id-type="pmid">34981981</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cheng</surname> <given-names>Z</given-names></name>
<name><surname>Wang</surname> <given-names>S</given-names></name>
<name><surname>Xu</surname> <given-names>S</given-names></name>
<name><surname>Du</surname> <given-names>B</given-names></name>
<name><surname>Li</surname> <given-names>X</given-names></name>
<name><surname>Li</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>FAPI PET/CT in diagnostic and treatment management of colorectal cancer: Review of current research status</article-title>. <source>J Clin Med</source>. (<year>2023</year>) <volume>12</volume>:<elocation-id>577</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/jcm12020577</pub-id>, PMID: <pub-id pub-id-type="pmid">36675506</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nasim</surname> <given-names>F</given-names></name>
<name><surname>Sabath</surname> <given-names>BF</given-names></name>
<name><surname>Eapen</surname> <given-names>GA</given-names></name>
</person-group>. 
<article-title>Lung cancer</article-title>. <source>Med Clin North Am</source>. (<year>2019</year>) <volume>103</volume>:<page-range>463&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mcna.2018.12.006</pub-id>, PMID: <pub-id pub-id-type="pmid">30955514</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Giesel</surname> <given-names>FL</given-names></name>
<name><surname>Adeberg</surname> <given-names>S</given-names></name>
<name><surname>Syed</surname> <given-names>M</given-names></name>
<name><surname>Lindner</surname> <given-names>T</given-names></name>
<name><surname>Jim&#xe9;nez-Franco</surname> <given-names>LD</given-names></name>
<name><surname>Mavriopoulou</surname> <given-names>E</given-names></name>
<etal/>
</person-group>. 
<article-title>FAPI-74 PET/CT using either 18F-AlF or cold-kit 68Ga labeling: Biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients</article-title>. <source>J Nucl Med</source>. (<year>2021</year>) <volume>62</volume>:<page-range>201&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.120.245084</pub-id>, PMID: <pub-id pub-id-type="pmid">32591493</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wei</surname> <given-names>Y</given-names></name>
<name><surname>Ma</surname> <given-names>L</given-names></name>
<name><surname>Li</surname> <given-names>P</given-names></name>
<etal/>
</person-group>. 
<article-title>FAPI compared with FDG PET/CT for diagnosis of primary and metastatic lung cancer</article-title>. <source>Radiology</source>. (<year>2023</year>) <volume>308</volume>:<elocation-id>e222785</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.222785</pub-id>, PMID: <pub-id pub-id-type="pmid">37552075</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname> <given-names>Y</given-names></name>
<name><surname>Sun</surname> <given-names>Y</given-names></name>
<name><surname>Li</surname> <given-names>Z</given-names></name>
<etal/>
</person-group>. 
<article-title>18F-FAPI PET/CT performs better in evaluating mediastinal and hilar lymph nodes in patients with lung cancer: Comparison with 18F-FDG PET/CT</article-title>. <source>Eur J Med Res</source>. (<year>2024</year>) <volume>29</volume>:<elocation-id>9</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40001-023-01494-9</pub-id>, PMID: <pub-id pub-id-type="pmid">38173034</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname> <given-names>Y</given-names></name>
<name><surname>Zhang</surname> <given-names>Y</given-names></name>
<name><surname>Guo</surname> <given-names>Z</given-names></name>
<etal/>
</person-group>. 
<article-title>18F]FAPI adds value to [18F]FDG PET/CT for diagnosing lymph node metastases in stage I-IIIA non-small cell lung cancer: A prospective study</article-title>. <source>Cancer Imaging</source>. (<year>2024</year>) <volume>24</volume>:<fpage>68</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40644-024-00701-y</pub-id>, PMID: <pub-id pub-id-type="pmid">38831354</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Qin</surname> <given-names>J</given-names></name>
<name><surname>Han</surname> <given-names>C</given-names></name>
<name><surname>Li</surname> <given-names>H</given-names></name>
<etal/>
</person-group>. 
<article-title>Relationship between PD-L1 expression and [18F]FAPI versus [18F]FDG uptake on PET/CT in lung cancer</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2025</year>) <volume>52</volume>:<page-range>3211&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-025-07201-6</pub-id>, PMID: <pub-id pub-id-type="pmid">40113644</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>L</given-names></name>
<name><surname>Tang</surname> <given-names>G</given-names></name>
<name><surname>Hu</surname> <given-names>K</given-names></name>
<etal/>
</person-group>. 
<article-title>Comparison of<sup>68</sup> ga-FAPI and<sup>18</sup> F-FDG PET/CT in the evaluation of advanced lung cancer</article-title>. <source>Radiology</source>. (<year>2022</year>) <volume>303</volume>:<page-range>191&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.211424</pub-id>, PMID: <pub-id pub-id-type="pmid">34981976</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Can</surname> <given-names>C</given-names></name>
<name><surname>Kepenek</surname> <given-names>F</given-names></name>
<name><surname>K&#xf6;mek</surname> <given-names>H</given-names></name>
<etal/>
</person-group>. 
<article-title>Comparison of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT in patients with non-small cell lung cancer</article-title>. <source>Nucl Med Commun</source>. (<year>2022</year>) <volume>43</volume>:<page-range>1084&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MNM.0000000000001607</pub-id>, PMID: <pub-id pub-id-type="pmid">35972340</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname> <given-names>Q</given-names></name>
<name><surname>Huang</surname> <given-names>D</given-names></name>
<name><surname>Wu</surname> <given-names>J</given-names></name>
<name><surname>Zhong</surname> <given-names>H</given-names></name>
<name><surname>Han</surname> <given-names>Y</given-names></name>
<name><surname>Jiang</surname> <given-names>H</given-names></name>
<etal/>
</person-group>. 
<article-title>Performance of [18F]FDG PET/CT versus FAPI PET/CT for lung cancer assessment: A systematic review and meta-analysis</article-title>. <source>Eur Radiol</source>. (<year>2023</year>) <volume>34</volume>:<page-range>1077&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00330-023-10013-7</pub-id>, PMID: <pub-id pub-id-type="pmid">37589901</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gu</surname> <given-names>B</given-names></name>
<name><surname>Luo</surname> <given-names>Z</given-names></name>
<name><surname>He</surname> <given-names>X</given-names></name>
<name><surname>Wang</surname> <given-names>J</given-names></name>
<name><surname>Song</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>68Ga-FAPI and 18F-FDG PET/CT images in a patient with extrapulmonary tuberculosis mimicking Malignant tumor</article-title>. <source>Clin Nucl Med</source>. (<year>2020</year>) <volume>45</volume>:<page-range>865&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000003279</pub-id>, PMID: <pub-id pub-id-type="pmid">32969904</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gaona-Luviano</surname> <given-names>P</given-names></name>
<name><surname>Medina-Gaona</surname> <given-names>LA</given-names></name>
<name><surname>Maga&#xf1;a-P&#xe9;rez</surname> <given-names>K</given-names></name>
</person-group>. 
<article-title>Epidemiology of ovarian cancer</article-title>. <source>Chin Clin Oncol</source>. (<year>2020</year>) <volume>9</volume>:<page-range>47&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/cco-20-34</pub-id>, PMID: <pub-id pub-id-type="pmid">32648448</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>J</given-names></name>
<name><surname>Xu</surname> <given-names>K</given-names></name>
<name><surname>Li</surname> <given-names>C</given-names></name>
<name><surname>Tian</surname> <given-names>Y</given-names></name>
<name><surname>Li</surname> <given-names>L</given-names></name>
<name><surname>Wen</surname> <given-names>B</given-names></name>
<etal/>
</person-group>. 
<article-title>68Ga]ga-FAPI-04 PET/CT in the evaluation of epithelial ovarian cancer: Comparison with [18F]F-FDG PET/CT</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2023</year>) <volume>50</volume>:<page-range>4064&#x2013;76</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-023-06369-z</pub-id>, PMID: <pub-id pub-id-type="pmid">37526694</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>Y</given-names></name>
<name><surname>Pan</surname> <given-names>J</given-names></name>
<name><surname>Jing</surname> <given-names>F</given-names></name>
<name><surname>Chen</surname> <given-names>X</given-names></name>
<name><surname>Zhao</surname> <given-names>X</given-names></name>
<name><surname>Zhang</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT in diagnosing ovarian cancer</article-title>. <source>Abdom Radiol</source>. (<year>2024</year>) <volume>49</volume>:<page-range>4531&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00261-024-04469-4</pub-id>, PMID: <pub-id pub-id-type="pmid">38937339</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>S</given-names></name>
<name><surname>Feng</surname> <given-names>Z</given-names></name>
<name><surname>Xu</surname> <given-names>X</given-names></name>
<name><surname>Ge</surname> <given-names>H</given-names></name>
<name><surname>Ju</surname> <given-names>X</given-names></name>
<name><surname>Wu</surname> <given-names>X</given-names></name>
<etal/>
</person-group>. 
<article-title>Head-to-head comparison of [18F]-FDG and [68 Ga]-DOTA-FAPI-04 PET/CT for radiological evaluation of platinum-sensitive recurrent ovarian cancer</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2023</year>) <volume>50</volume>:<page-range>1521&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-022-06096-x</pub-id>, PMID: <pub-id pub-id-type="pmid">36624168</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zheng</surname> <given-names>W</given-names></name>
<name><surname>Liu</surname> <given-names>L</given-names></name>
<name><surname>Feng</surname> <given-names>Y</given-names></name>
<name><surname>Wang</surname> <given-names>L</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian Malignancies</article-title>. <source>Nucl Med Commun</source>. (<year>2023</year>) <volume>44</volume>:<fpage>194</fpage>&#x2013;<lpage>203</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MNM.0000000000001653</pub-id>, PMID: <pub-id pub-id-type="pmid">36472415</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xi</surname> <given-names>Y</given-names></name>
<name><surname>Sun</surname> <given-names>L</given-names></name>
<name><surname>Che</surname> <given-names>X</given-names></name>
<name><surname>Huang</surname> <given-names>X</given-names></name>
<name><surname>Liu</surname> <given-names>H</given-names></name>
<name><surname>Wang</surname> <given-names>Q</given-names></name>
<etal/>
</person-group>. 
<article-title>A comparative study of [68Ga]ga-FAPI-04 PET/MR and [18F]FDG PET/CT in the diagnostic accuracy and resectability prediction of ovarian cancer</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2023</year>) <volume>50</volume>:<page-range>2885&#x2013;98</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-023-06235-y</pub-id>, PMID: <pub-id pub-id-type="pmid">37093313</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname> <given-names>L</given-names></name>
<name><surname>Hao</surname> <given-names>P</given-names></name>
<name><surname>Peng</surname> <given-names>R</given-names></name>
</person-group>. 
<article-title>Comparison of 68Ga-FAPI PET CT/MRI and 18F-FDG PET/CT in metastatic lesions of gynecological cancers: A systematic review and head-to-head meta-analysis</article-title>. <source>Acta Radiol</source>. (<year>2025</year>) <volume>66</volume>:<page-range>174&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/02841851241297836</pub-id>, PMID: <pub-id pub-id-type="pmid">39676354</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Anastasiadi</surname> <given-names>Z</given-names></name>
<name><surname>Lianos</surname> <given-names>GD</given-names></name>
<name><surname>Ignatiadou</surname> <given-names>E</given-names></name>
<name><surname>Harissis</surname> <given-names>HV</given-names></name>
<name><surname>Mitsis</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Breast cancer in young women: An overview</article-title>. <source>Update Surg</source>. (<year>2017</year>) <volume>69</volume>:<page-range>313&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s13304-017-0424-1</pub-id>, PMID: <pub-id pub-id-type="pmid">28260181</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>K&#xf6;mek</surname> <given-names>H</given-names></name>
<name><surname>Can</surname> <given-names>C</given-names></name>
<name><surname>G&#xfc;zel</surname> <given-names>Y</given-names></name>
<name><surname>Arslan</surname> <given-names>A</given-names></name>
<name><surname>G&#xfc;ler</surname> <given-names>H</given-names></name>
<name><surname>&#xd6;zkan</surname> <given-names>E</given-names></name>
<etal/>
</person-group>. 
<article-title>68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: A comparative pilot study with the 18F-FDG PET/CT</article-title>. <source>Ann Nucl Med</source>. (<year>2021</year>) <volume>35</volume>:<page-range>744&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12149-021-01616-5</pub-id>, PMID: <pub-id pub-id-type="pmid">33934311</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zheng</surname> <given-names>S</given-names></name>
<name><surname>Lin</surname> <given-names>J</given-names></name>
<name><surname>Zhu</surname> <given-names>Y</given-names></name>
<name><surname>Chen</surname> <given-names>L</given-names></name>
<name><surname>Wang</surname> <given-names>X</given-names></name>
<name><surname>Cheng</surname> <given-names>Z</given-names></name>
<etal/>
</person-group>. 
<article-title>68Ga-FAPI versus 18F-FDG PET/CT in evaluating newly diagnosed breast cancer patients: A head-to-head&#xa0;comparative study</article-title>. <source>Clin Nucl Med</source>. (<year>2023</year>) <volume>48</volume>:<page-range>e104&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000004523</pub-id>, PMID: <pub-id pub-id-type="pmid">36723892</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Al&#x131;n</surname> <given-names>G</given-names></name>
<name><surname>Arslan</surname> <given-names>E</given-names></name>
<name><surname>Aksoy</surname> <given-names>T</given-names></name>
<name><surname>Uslu</surname> <given-names>M</given-names></name>
<name><surname>&#xd6;zt&#xfc;rk</surname> <given-names>M</given-names></name>
<name><surname>Y&#x131;lmaz</surname> <given-names>F</given-names></name>
<etal/>
</person-group>. 
<article-title>68Ga-FAPI-04 PET/CT in selected breast cancer patients with low FDG affinity: A head-to-head comparative study</article-title>. <source>Clin Nucl Med</source>. (<year>2023</year>) <volume>48</volume>:<page-range>e420&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000004751</pub-id>, PMID: <pub-id pub-id-type="pmid">37351868</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>Q</given-names></name>
<name><surname>Tang</surname> <given-names>W</given-names></name>
<name><surname>Cai</surname> <given-names>L</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>Non-18F-FDG-avid intrahepatic metastasis of breast cancer revealed by 68Ga-FAPI PET/CT</article-title>. <source>Clin Nucl Med</source>. (<year>2022</year>) <volume>47</volume>:<page-range>228&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000003905</pub-id>, PMID: <pub-id pub-id-type="pmid">34653058</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hirmas</surname> <given-names>N</given-names></name>
<name><surname>Hamacher</surname> <given-names>R</given-names></name>
<name><surname>Sraieb</surname> <given-names>M</given-names></name>
<name><surname>Kessler</surname> <given-names>L</given-names></name>
<name><surname>Pabst</surname> <given-names>KM</given-names></name>
<name><surname>Barbato</surname> <given-names>F</given-names></name>
<etal/>
</person-group>. 
<article-title>Diagnostic accuracy of<sup>68</sup> ga-FAPI Versus<sup>18</sup> F-FDG PET in patients with various Malignancies</article-title>. <source>J Nucl Med</source>. (<year>2024</year>) <volume>65</volume>:<page-range>372&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.123.266652</pub-id>, PMID: <pub-id pub-id-type="pmid">38331453</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Guglielmo</surname> <given-names>P</given-names></name>
<name><surname>Alongi</surname> <given-names>P</given-names></name>
<name><surname>Baratto</surname> <given-names>L</given-names></name>
<name><surname>Abenavoli</surname> <given-names>E</given-names></name>
<name><surname>Buschiazzo</surname> <given-names>A</given-names></name>
<name><surname>Celesti</surname> <given-names>G</given-names></name>
<etal/>
</person-group>. 
<article-title>Head-to-head comparison of FDG and radiolabeled FAPI PET: A systematic review of the literature</article-title>. <source>Life</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>1821</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/life13091821</pub-id>, PMID: <pub-id pub-id-type="pmid">37763225</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Salazar</surname> <given-names>J</given-names></name>
<name><surname>Le</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>The heterogeneity of liver cancer metabolism</article-title>. <source>Adv Exp Med Biol</source>. (<year>2021</year>) <volume>1311</volume>:<page-range>127&#x2013;36</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-3-030-65768-0_9</pub-id>, PMID: <pub-id pub-id-type="pmid">34014539</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Guo</surname> <given-names>W</given-names></name>
<name><surname>Pang</surname> <given-names>Y</given-names></name>
<name><surname>Yao</surname> <given-names>L</given-names></name>
<name><surname>Zhao</surname> <given-names>L</given-names></name>
<name><surname>Fan</surname> <given-names>C</given-names></name>
<name><surname>Ke</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Imaging fibroblast activation protein in liver cancer: A single-center <italic>post hoc</italic> retrospective analysis to compare [68Ga]ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2021</year>) <volume>48</volume>:<page-range>1604&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-020-05095-0</pub-id>, PMID: <pub-id pub-id-type="pmid">33179149</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liang</surname> <given-names>Z</given-names></name>
<name><surname>Peng</surname> <given-names>H</given-names></name>
<name><surname>Li</surname> <given-names>W</given-names></name>
<name><surname>Liu</surname> <given-names>Z</given-names></name>
</person-group>. 
<article-title>Head-to-head study of [18F]FAPI-04 PET/CT and [18F]FDG PET/CT for non-invasive assessment of liver cancer and its immunohistochemical markers</article-title>. <source>BMC Cancer</source>. (<year>2024</year>) <volume>24</volume>:<fpage>1378</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12885-024-13153-1</pub-id>, PMID: <pub-id pub-id-type="pmid">39528951</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>H</given-names></name>
<name><surname>Zhu</surname> <given-names>W</given-names></name>
<name><surname>Ren</surname> <given-names>S</given-names></name>
<name><surname>Kong</surname> <given-names>Y</given-names></name>
<name><surname>Huang</surname> <given-names>Q</given-names></name>
<name><surname>Zhao</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>68Ga-FAPI-04 versus 18F-FDG PET/CT in the detection of hepatocellular carcinoma</article-title>. <source>Front Oncol</source>. (<year>2021</year>) <volume>11</volume>:<elocation-id>693640</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2021.693640</pub-id>, PMID: <pub-id pub-id-type="pmid">34249748</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname> <given-names>J</given-names></name>
<name><surname>Jiang</surname> <given-names>S</given-names></name>
<name><surname>Li</surname> <given-names>M</given-names></name>
<name><surname>Xue</surname> <given-names>H</given-names></name>
<name><surname>Zhong</surname> <given-names>X</given-names></name>
<name><surname>Li</surname> <given-names>S</given-names></name>
<etal/>
</person-group>. 
<article-title>Head-to-head comparison of 18F-FAPI and 18F-FDG PET/CT in staging and therapeutic management of hepatocellular carcinoma</article-title>. <source>Cancer Imaging</source>. (<year>2023</year>) <volume>23</volume>:<fpage>106</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40644-023-00626-y</pub-id>, PMID: <pub-id pub-id-type="pmid">37899452</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname> <given-names>P</given-names></name>
<name><surname>Singhal</surname> <given-names>T</given-names></name>
<name><surname>Parida</surname> <given-names>GK</given-names></name>
<name><surname>Rahman</surname> <given-names>A</given-names></name>
<name><surname>Agrawal</surname> <given-names>K</given-names></name>
</person-group>. 
<article-title>Diagnostic performance of FAPI PET/CT vs. 18F-FDG PET/CT in evaluation of liver tumors: A systematic review and meta-analysis</article-title>. <source>Mol Imaging Radionucl Ther</source>. (<year>2022</year>) <volume>33</volume>:<fpage>77</fpage>&#x2013;<lpage>89</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4274/mirt.galenos.2024.99705</pub-id>, PMID: <pub-id pub-id-type="pmid">38949417</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ilic</surname> <given-names>M</given-names></name>
<name><surname>Ilic</surname> <given-names>I</given-names></name>
</person-group>. 
<article-title>Epidemiology of pancreatic cancer</article-title>. <source>World J Gastroenterol</source>. (<year>2016</year>) <volume>22</volume>:<page-range>9694&#x2013;705</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3748/wjg.v22.i44.9694</pub-id>, PMID: <pub-id pub-id-type="pmid">27956793</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Veldhuijzen van Zanten</surname> <given-names>SEM</given-names></name>
<name><surname>Pieterman</surname> <given-names>KJ</given-names></name>
<name><surname>Wijnhoven</surname> <given-names>BPL</given-names></name>
<name><surname>Pruis</surname> <given-names>IJ</given-names></name>
<name><surname>Groot Koerkamp</surname> <given-names>B</given-names></name>
<name><surname>van Driel</surname> <given-names>LMJW</given-names></name>
<etal/>
</person-group>. 
<article-title>FAPI PET versus FDG PET, CT or MRI for staging pancreatic-, gastric- and cholangiocarcinoma: Systematic review and head-to-head comparisons of diagnostic performances</article-title>. <source>Diagnostics</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>1958</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/diagnostics12081958</pub-id>, PMID: <pub-id pub-id-type="pmid">36010308</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname> <given-names>X</given-names></name>
<name><surname>Li</surname> <given-names>X</given-names></name>
<name><surname>Wang</surname> <given-names>P</given-names></name>
<name><surname>Cai</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>The role of FAPI PET imaging in pancreatic cancer: a meta-analysis compared with 18F-FDG PET</article-title>. <source>Acad Radiol</source>. (<year>2025</year>) <volume>32</volume>:<fpage>191</fpage>&#x2013;<lpage>200</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.acra.2024.07.032</pub-id>, PMID: <pub-id pub-id-type="pmid">39097507</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>Q</given-names></name>
<name><surname>Shi</surname> <given-names>S</given-names></name>
<name><surname>Liu</surname> <given-names>S</given-names></name>
<name><surname>Xu</surname> <given-names>X</given-names></name>
<name><surname>Hu</surname> <given-names>S</given-names></name>
<name><surname>Zhang</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>The added value of [68Ga]ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: A comparison to [18F]F-FDG</article-title>. <source>Eur Radiol</source>. (<year>2023</year>) <volume>33</volume>:<page-range>5007&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00330-023-09445-y</pub-id>, PMID: <pub-id pub-id-type="pmid">36809431</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yun</surname> <given-names>WG</given-names></name>
<name><surname>Gil</surname> <given-names>J</given-names></name>
<name><surname>Choi</surname> <given-names>H</given-names></name>
<name><surname>Han</surname> <given-names>Y</given-names></name>
<name><surname>Jung</surname> <given-names>HS</given-names></name>
<name><surname>Cho</surname> <given-names>YJ</given-names></name>
<etal/>
</person-group>. 
<article-title>Prospective comparison of [18F]FDG and [18F]AIF-FAPI-74 PET/CT in the evaluation of potentially resectable pancreatic ductal adenocarcinoma</article-title>. <source>Mol Imaging Biol</source>. (<year>2024</year>) <volume>26</volume>:<page-range>1068&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11307-024-01950-w</pub-id>, PMID: <pub-id pub-id-type="pmid">39365411</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Karimi</surname> <given-names>P</given-names></name>
<name><surname>Islami</surname> <given-names>F</given-names></name>
<name><surname>Anandasabapathy</surname> <given-names>S</given-names></name>
<name><surname>Freedman</surname> <given-names>ND</given-names></name>
<name><surname>Kamangar</surname> <given-names>F</given-names></name>
</person-group>. 
<article-title>Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. (<year>2014</year>) <volume>23</volume>:<page-range>700&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/1055-9965.EPI-13-1057</pub-id>, PMID: <pub-id pub-id-type="pmid">24618998</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>B</given-names></name>
<name><surname>Zhao</surname> <given-names>X</given-names></name>
<name><surname>Liu</surname> <given-names>Y</given-names></name>
<name><surname>Zhang</surname> <given-names>Z</given-names></name>
<name><surname>Chen</surname> <given-names>X</given-names></name>
<name><surname>Jing</surname> <given-names>F</given-names></name>
<etal/>
</person-group>. 
<article-title>Comparison of 68Ga-FAPI-04 PET/CT with 18F-FDG PET/CT for diagnosis and staging of gastric and colorectal cancer</article-title>. <source>Nucl Med Commun</source>. (<year>2024</year>) <volume>45</volume>:<page-range>612&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MNM.0000000000001845</pub-id>, PMID: <pub-id pub-id-type="pmid">38686487</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Miao</surname> <given-names>Y</given-names></name>
<name><surname>Feng</surname> <given-names>R</given-names></name>
<name><surname>Yu</surname> <given-names>T</given-names></name>
<name><surname>Guo</surname> <given-names>R</given-names></name>
<name><surname>Zhang</surname> <given-names>M</given-names></name>
<name><surname>Wang</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>Value of<sup>68</sup> ga-FAPI-04 and<sup>18</sup> F-FDG PET/CT in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer</article-title>. <source>J Nucl Med</source>. (<year>2024</year>) <volume>65</volume>:<page-range>213&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.123.266403</pub-id>, PMID: <pub-id pub-id-type="pmid">38164574</pub-id>
</mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ruan</surname> <given-names>D</given-names></name>
<name><surname>Zhao</surname> <given-names>L</given-names></name>
<name><surname>Cai</surname> <given-names>J</given-names></name>
<name><surname>Xu</surname> <given-names>W</given-names></name>
<name><surname>Sun</surname> <given-names>L</given-names></name>
<name><surname>Li</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Evaluation of FAPI PET imaging in gastric cancer: A systematic review and meta-analysis</article-title>. <source>Theranostics</source>. (<year>2023</year>) <volume>13</volume>:<page-range>4694&#x2013;710</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/thno.88335</pub-id>, PMID: <pub-id pub-id-type="pmid">37649615</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kuten</surname> <given-names>J</given-names></name>
<name><surname>Levine</surname> <given-names>C</given-names></name>
<name><surname>Shamni</surname> <given-names>O</given-names></name>
<name><surname>Pelles</surname> <given-names>S</given-names></name>
<name><surname>Wolf</surname> <given-names>I</given-names></name>
<name><surname>Lahat</surname> <given-names>G</given-names></name>
<etal/>
</person-group>. 
<article-title>Head-to-head comparison of [68Ga]ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2022</year>) <volume>49</volume>:<page-range>743&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-021-05494-x</pub-id>, PMID: <pub-id pub-id-type="pmid">34302504</pub-id>
</mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Qin</surname> <given-names>C</given-names></name>
<name><surname>Shao</surname> <given-names>F</given-names></name>
<name><surname>Gai</surname> <given-names>Y</given-names></name>
<name><surname>Liu</surname> <given-names>Q</given-names></name>
<name><surname>Ruan</surname> <given-names>W</given-names></name>
<name><surname>Liu</surname> <given-names>F</given-names></name>
<etal/>
</person-group>. 
<article-title>68Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: Comparison with 18F-FDG PET/CT</article-title>. <source>J Nucl Med</source>. (<year>2022</year>) <volume>63</volume>:<page-range>81&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.120.258467</pub-id>, PMID: <pub-id pub-id-type="pmid">33863819</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Du</surname> <given-names>T</given-names></name>
<name><surname>Zhang</surname> <given-names>S</given-names></name>
<name><surname>Cui</surname> <given-names>XM</given-names></name>
<name><surname>Hu</surname> <given-names>RH</given-names></name>
<name><surname>Wang</surname> <given-names>HY</given-names></name>
<name><surname>Jiang</surname> <given-names>JJ</given-names></name>
<etal/>
</person-group>. 
<article-title>Comparison of [68Ga]ga-DOTA-FAPI-04 and [18F]FDG PET/MRI in the preoperative diagnosis of gastric cancer</article-title>. <source>Can J Gastroenterol Hepatol</source>. (<year>2023</year>) <volume>2023</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2023/6351330</pub-id>, PMID: <pub-id pub-id-type="pmid">37090103</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kiran</surname> <given-names>MY</given-names></name>
<name><surname>Ercan</surname> <given-names>LD</given-names></name>
<name><surname>Karatay</surname> <given-names>E</given-names></name>
<name><surname>Has Simsek</surname> <given-names>D</given-names></name>
<name><surname>Sanli</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>Unusual metastasis of signet-ring cell gastric cancer that could not be detected with 18F-FDG PET but with 68Ga-FAPI PET/CT</article-title>. <source>Clin Nucl Med</source>. (<year>2024</year>) <volume>49</volume>:<page-range>e215&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000005154</pub-id>, PMID: <pub-id pub-id-type="pmid">38537207</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Miao</surname> <given-names>Y</given-names></name>
<name><surname>Feng</surname> <given-names>R</given-names></name>
<name><surname>Guo</surname> <given-names>R</given-names></name>
<name><surname>Huang</surname> <given-names>X</given-names></name>
<name><surname>Hai</surname> <given-names>W</given-names></name>
<name><surname>Li</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Utility of [68Ga]FAPI-04 and [18F]FDG dual-tracer PET/CT in the initial evaluation of gastric cancer</article-title>. <source>Eur Radiol</source>. (<year>2023</year>) <volume>33</volume>:<page-range>4355&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00330-022-09321-1</pub-id>, PMID: <pub-id pub-id-type="pmid">36522509</pub-id>
</mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pang</surname> <given-names>Y</given-names></name>
<name><surname>Zhao</surname> <given-names>L</given-names></name>
<name><surname>Luo</surname> <given-names>Z</given-names></name>
<name><surname>Hao</surname> <given-names>B</given-names></name>
<name><surname>Wu</surname> <given-names>H</given-names></name>
<name><surname>Lin</surname> <given-names>Q</given-names></name>
<etal/>
</person-group>. 
<article-title>Comparison of<sup>68</sup> ga-FAPI and<sup>18</sup> F-FDG uptake in gastric, duodenal, and colorectal cancers</article-title>. <source>Radiology</source>. (<year>2021</year>) <volume>298</volume>:<fpage>393</fpage>&#x2013;<lpage>402</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.2020203275</pub-id>, PMID: <pub-id pub-id-type="pmid">33258746</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname> <given-names>X</given-names></name>
<name><surname>Zhao</surname> <given-names>J</given-names></name>
<name><surname>Qi</surname> <given-names>G</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
<name><surname>Guo</surname> <given-names>X</given-names></name>
<name><surname>Zhang</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>USP48 inhibits colorectal cancer progression and promotes M1-like macrophage polarization by stabilizing TAK1</article-title>. <source>Exp Cell Res</source>. (<year>2025</year>) <volume>446</volume>:<elocation-id>114469</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yexcr.2025.114469</pub-id>, PMID: <pub-id pub-id-type="pmid">39971179</pub-id>
</mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>J</given-names></name>
<name><surname>Bai</surname> <given-names>X</given-names></name>
<name><surname>Du</surname> <given-names>J</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
<name><surname>Guo</surname> <given-names>X</given-names></name>
<name><surname>Zhang</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Tryptophan metabolism: From physiological functions to key roles and therapeutic targets in cancer (Review)</article-title>. <source>Oncol Rep</source>. (<year>2025</year>) <volume>54</volume>:<fpage>1</fpage>&#x2013;<lpage>16</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/or.2025.8919</pub-id>, PMID: <pub-id pub-id-type="pmid">40444491</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dong</surname> <given-names>Y</given-names></name>
<name><surname>Sun</surname> <given-names>P</given-names></name>
<name><surname>Wu</surname> <given-names>H</given-names></name>
<name><surname>Zhong</surname> <given-names>J</given-names></name>
<name><surname>Cao</surname> <given-names>M</given-names></name>
<name><surname>Tang</surname> <given-names>G</given-names></name>
<etal/>
</person-group>. 
<article-title>PET/CT imaging fibroblast activation protein in initial colorectal cancer: Compared to 18F-FDG PET/CT</article-title>. <source>Nucl Med Commun</source>. (<year>2023</year>) <volume>44</volume>:<page-range>1011&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MNM.0000000000001751</pub-id>, PMID: <pub-id pub-id-type="pmid">37661771</pub-id>
</mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhuang</surname> <given-names>Z</given-names></name>
<name><surname>Zhang</surname> <given-names>Y</given-names></name>
<name><surname>Yang</surname> <given-names>X</given-names></name>
<name><surname>Deng</surname> <given-names>X</given-names></name>
<name><surname>Wang</surname> <given-names>Z</given-names></name>
</person-group>. 
<article-title>Head-to-head comparison of the diagnostic performance between 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT in colorectal cancer: A systematic review and meta-analysis</article-title>. <source>Abdom Radiol</source>. (<year>2024</year>) <volume>49</volume>:<page-range>3166&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00261-024-04266-z</pub-id>, PMID: <pub-id pub-id-type="pmid">38587629</pub-id>
</mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>K&#xf6;mek</surname> <given-names>H</given-names></name>
<name><surname>Can</surname> <given-names>C</given-names></name>
<name><surname>Kaplan</surname> <given-names>&#x130;</given-names></name>
<name><surname>G&#xfc;ndo&#x11f;an</surname> <given-names>C</given-names></name>
<name><surname>Kepenek</surname> <given-names>F</given-names></name>
<name><surname>Karao&#x11f;lan</surname> <given-names>H</given-names></name>
<etal/>
</person-group>. 
<article-title>Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2022</year>) <volume>49</volume>:<page-range>3898&#x2013;909</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-022-05839-0</pub-id>, PMID: <pub-id pub-id-type="pmid">35578038</pub-id>
</mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xi</surname> <given-names>Y</given-names></name>
<name><surname>Sun</surname> <given-names>Y</given-names></name>
<name><surname>Gu</surname> <given-names>B</given-names></name>
<name><surname>Bian</surname> <given-names>L</given-names></name>
<name><surname>Song</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Evaluation of 68Ga-FAPI PET/CT and 18F-FDG PET/CT for the diagnosis of recurrent colorectal cancers</article-title>. <source>Clin Transl Radiat Oncol</source>. (<year>2024</year>) <volume>49</volume>:<elocation-id>100848</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ctro.2024.100848</pub-id>, PMID: <pub-id pub-id-type="pmid">39290456</pub-id>
</mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Elekonawo</surname> <given-names>FMK</given-names></name>
<name><surname>Starremans</surname> <given-names>B</given-names></name>
<name><surname>Laurens</surname> <given-names>ST</given-names></name>
<name><surname>Bremers</surname> <given-names>AJA</given-names></name>
<name><surname>de Wilt</surname> <given-names>JHW</given-names></name>
<name><surname>Heijmen</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Can [18F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer</article-title>? <source>Abdom Radiol</source>. (<year>2020</year>) <volume>45</volume>:<page-range>301&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00261-019-02268-w</pub-id>, PMID: <pub-id pub-id-type="pmid">31642963</pub-id>
</mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Prashanth</surname> <given-names>A</given-names></name>
<name><surname>Kumar Ravichander</surname> <given-names>S</given-names></name>
<name><surname>Eswaran</surname> <given-names>P</given-names></name>
<name><surname>Kalyan</surname> <given-names>S</given-names></name>
<name><surname>Maheswari Babu</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Diagnostic performance of ga-68 FAPI 04 PET/CT in colorectal Malignancies</article-title>. <source>Nucl Med Commun</source>. (<year>2023</year>) <volume>44</volume>:<page-range>276&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MNM.0000000000001661</pub-id>, PMID: <pub-id pub-id-type="pmid">36756771</pub-id>
</mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kratochwil</surname> <given-names>C</given-names></name>
<name><surname>Flechsig</surname> <given-names>P</given-names></name>
<name><surname>Lindner</surname> <given-names>T</given-names></name>
<name><surname>Abderrahim</surname> <given-names>L</given-names></name>
<name><surname>Altmann</surname> <given-names>A</given-names></name>
<name><surname>Mier</surname> <given-names>W</given-names></name>
<etal/>
</person-group>. 
<article-title>68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer</article-title>. <source>J Nucl Med</source>. (<year>2019</year>) <volume>60</volume>:<page-range>801&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.119.227967</pub-id>, PMID: <pub-id pub-id-type="pmid">30954939</pub-id>
</mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname> <given-names>X</given-names></name>
<name><surname>Li</surname> <given-names>Y</given-names></name>
<name><surname>Wang</surname> <given-names>S</given-names></name>
<name><surname>Zhang</surname> <given-names>Y</given-names></name>
<name><surname>Chen</surname> <given-names>X</given-names></name>
<name><surname>Wei</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Diagnostic value of [68Ga]ga-FAPI-04 in patients with colorectal cancer in comparison with [18F]F-FDG PET/CT</article-title>. <source>Front Oncol</source>. (<year>2023</year>) <volume>12</volume>:<elocation-id>1087792</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.1087792</pub-id>, PMID: <pub-id pub-id-type="pmid">36698416</pub-id>
</mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fu</surname> <given-names>C</given-names></name>
<name><surname>Zhang</surname> <given-names>B</given-names></name>
<name><surname>Guo</surname> <given-names>T</given-names></name>
<name><surname>Li</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Imaging evaluation of peritoneal metastasis: Current and promising techniques</article-title>. <source>Korean J Radiol</source>. (<year>2024</year>) <volume>25</volume>:<fpage>86</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3348/kjr.2023.0840</pub-id>, PMID: <pub-id pub-id-type="pmid">38184772</pub-id>
</mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dondi</surname> <given-names>F</given-names></name>
<name><surname>Albano</surname> <given-names>D</given-names></name>
<name><surname>Giubbini</surname> <given-names>R</given-names></name>
<name><surname>Bertagna</surname> <given-names>F</given-names></name>
</person-group>. 
<article-title>18F-FDG PET and PET/CT for the evaluation of gastric signet ring cell carcinoma: A systematic review</article-title>. <source>Nucl Med Commun</source>. (<year>2021</year>) <volume>42</volume>:<page-range>1293&#x2013;300</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MNM.0000000000001481</pub-id>, PMID: <pub-id pub-id-type="pmid">34456317</pub-id>
</mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gege</surname> <given-names>Z</given-names></name>
<name><surname>Xueju</surname> <given-names>W</given-names></name>
<name><surname>Bin</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Head-to-head comparison of<sup>68</sup> ga-FAPI PET/CT and FDG PET/CT for the detection of peritoneal metastases: Systematic review and meta-analysis</article-title>. <source>Am J Roentgenol</source>. (<year>2023</year>) <volume>220</volume>:<page-range>490&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2214/AJR.22.28402</pub-id>, PMID: <pub-id pub-id-type="pmid">36321984</pub-id>
</mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname> <given-names>X</given-names></name>
<name><surname>Zhang</surname> <given-names>R</given-names></name>
<name><surname>Zheng</surname> <given-names>Q</given-names></name>
<name><surname>He</surname> <given-names>Z</given-names></name>
<name><surname>Lan</surname> <given-names>B</given-names></name>
<name><surname>Zhong</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>18F-FAPI-42 PET/CT enhances the diagnostic efficacy for peritoneal metastasis of colorectal cancer and guides treatment decisions: An original retrospective study</article-title>. <source>Gastroenterol Rep</source>. (<year>2024</year>) <volume>12</volume>:<elocation-id>goae104</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/gastro/goae104</pub-id>, PMID: <pub-id pub-id-type="pmid">39678162</pub-id>
</mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>L</given-names></name>
<name><surname>Pang</surname> <given-names>Y</given-names></name>
<name><surname>Luo</surname> <given-names>Z</given-names></name>
<name><surname>Fu</surname> <given-names>K</given-names></name>
<name><surname>Yang</surname> <given-names>T</given-names></name>
<name><surname>Zhao</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Role of [68Ga]ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2021</year>) <volume>48</volume>:<page-range>1944&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-020-05146-6</pub-id>, PMID: <pub-id pub-id-type="pmid">33415432</pub-id>
</mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>X</given-names></name>
<name><surname>Pang</surname> <given-names>X</given-names></name>
<name><surname>Zhao</surname> <given-names>Y</given-names></name>
<name><surname>Zhao</surname> <given-names>X</given-names></name>
<name><surname>Liu</surname> <given-names>Y</given-names></name>
<name><surname>Jing</surname> <given-names>F</given-names></name>
<etal/>
</person-group>. 
<article-title>68Ga-DOTA-FAPI-04 and 18F-FDG PET/CT: A head-to-head comparison for peritoneal carcinomatosis diagnostic accuracy</article-title>. <source>Abdom Radiol</source>. (<year>2025</year>) <volume>50</volume>:<page-range>3137&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00261-024-04653-6</pub-id>, PMID: <pub-id pub-id-type="pmid">39751881</pub-id>
</mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>G&#xfc;ndo&#x11f;an</surname> <given-names>C</given-names></name>
<name><surname>G&#xfc;zel</surname> <given-names>Y</given-names></name>
<name><surname>K&#xf6;mek</surname> <given-names>H</given-names></name>
<name><surname>Etem</surname> <given-names>H</given-names></name>
<name><surname>Kaplan</surname> <given-names>&#x130;</given-names></name>
</person-group>. 
<article-title>68Ga-FAPI-04 PET/CT versus 18F-FDG PET/CT in Malignant peritoneal mesothelioma</article-title>. <source>Clin Nucl Med</source>. (<year>2022</year>) <volume>47</volume>:<page-range>e113&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000003858</pub-id>, PMID: <pub-id pub-id-type="pmid">34392282</pub-id>
</mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lan</surname> <given-names>L</given-names></name>
<name><surname>Zhang</surname> <given-names>S</given-names></name>
<name><surname>Xu</surname> <given-names>T</given-names></name>
<name><surname>Liu</surname> <given-names>H</given-names></name>
<name><surname>Wang</surname> <given-names>W</given-names></name>
<name><surname>Feng</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>Prospective comparison of<sup>68</sup> ga-FAPI versus<sup>18</sup> F-FDG PET/CT for tumor staging in biliary tract cancers</article-title>. <source>Radiology</source>. (<year>2022</year>) <volume>304</volume>:<page-range>648&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.213118</pub-id>, PMID: <pub-id pub-id-type="pmid">35579524</pub-id>
</mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pabst</surname> <given-names>KM</given-names></name>
<name><surname>Trajkovic-Arsic</surname> <given-names>M</given-names></name>
<name><surname>Cheung</surname> <given-names>PFY</given-names></name>
<name><surname>Ballke</surname> <given-names>S</given-names></name>
<name><surname>Steiger</surname> <given-names>K</given-names></name>
<name><surname>Bartel</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>Superior tumor detection for 68Ga-FAPI-46 versus 18F-FDG PET/CT and conventional CT in patients with cholangiocarcinoma</article-title>. <source>J Nucl Med</source>. (<year>2023</year>) <volume>64</volume>:<page-range>1049&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.122.265215</pub-id>, PMID: <pub-id pub-id-type="pmid">37024301</pub-id>
</mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shu</surname> <given-names>Q</given-names></name>
<name><surname>He</surname> <given-names>X</given-names></name>
<name><surname>Chen</surname> <given-names>X</given-names></name>
<name><surname>Liu</surname> <given-names>M</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
<name><surname>Cai</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>Head-to-head comparison of 18F-FDG and 68Ga-FAPI-04 PET/CT for radiological evaluation of cervical cancer</article-title>. <source>Clin Nucl Med</source>. (<year>2023</year>) <volume>48</volume>:<page-range>928&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000004833</pub-id>, PMID: <pub-id pub-id-type="pmid">37756446</pub-id>
</mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ding</surname> <given-names>H</given-names></name>
<name><surname>Liang</surname> <given-names>J</given-names></name>
<name><surname>Qiu</surname> <given-names>L</given-names></name>
<name><surname>Xu</surname> <given-names>T</given-names></name>
<name><surname>Cai</surname> <given-names>L</given-names></name>
<name><surname>Wan</surname> <given-names>Q</given-names></name>
<etal/>
</person-group>. 
<article-title>Prospective comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT for tumor staging in nasopharyngeal carcinoma</article-title>. <source>Front Oncol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>1047010</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.1047010</pub-id>, PMID: <pub-id pub-id-type="pmid">36568172</pub-id>
</mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wegen</surname> <given-names>S</given-names></name>
<name><surname>Roth</surname> <given-names>KS</given-names></name>
<name><surname>Weindler</surname> <given-names>J</given-names></name>
<name><surname>Claus</surname> <given-names>K</given-names></name>
<name><surname>Linde</surname> <given-names>P</given-names></name>
<name><surname>Trommer</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>First clinical experience with [68Ga]Ga-FAPI-46-PET/CT versus [18F]F-FDG PET/CT for nodal staging in cervical cancer</article-title>. <source>Clin Nucl Med</source>. (<year>2023</year>) <volume>48</volume>:<page-range>150&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000004505</pub-id>, PMID: <pub-id pub-id-type="pmid">36607364</pub-id>
</mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Novruzov</surname> <given-names>E</given-names></name>
<name><surname>Dendl</surname> <given-names>K</given-names></name>
<name><surname>Ndlovu</surname> <given-names>H</given-names></name>
<name><surname>Choyke</surname> <given-names>PL</given-names></name>
<name><surname>Dabir</surname> <given-names>M</given-names></name>
<name><surname>Beu</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Head-to-head intra-individual comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in patients with bladder cancer</article-title>. <source>Mol Imaging Biol</source>. (<year>2022</year>) <volume>24</volume>:<page-range>651&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11307-022-01715-3</pub-id>, PMID: <pub-id pub-id-type="pmid">35349039</pub-id>
</mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mu</surname> <given-names>X</given-names></name>
<name><surname>Huang</surname> <given-names>X</given-names></name>
<name><surname>Jiang</surname> <given-names>Z</given-names></name>
<name><surname>Li</surname> <given-names>M</given-names></name>
<name><surname>Jia</surname> <given-names>L</given-names></name>
<name><surname>Lv</surname> <given-names>Z</given-names></name>
<etal/>
</person-group>. 
<article-title>18F]FAPI-42 PET/CT in differentiated thyroid cancer: Diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET/CT</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2023</year>) <volume>50</volume>:<page-range>1205&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-022-06067-2</pub-id>, PMID: <pub-id pub-id-type="pmid">36495325</pub-id>
</mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname> <given-names>J</given-names></name>
<name><surname>Zhang</surname> <given-names>S</given-names></name>
<name><surname>Rao</surname> <given-names>Z</given-names></name>
<name><surname>Wang</surname> <given-names>Y</given-names></name>
<name><surname>Zhang</surname> <given-names>C</given-names></name>
</person-group>. 
<article-title>Comparison of 68Ga-FAPI and 18F-FDG PET/CT in dermatofibrosarcoma protuberans</article-title>. <source>Clin Nucl Med</source>. (<year>2022</year>) <volume>47</volume>:<page-range>629&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000004212</pub-id>, PMID: <pub-id pub-id-type="pmid">35452009</pub-id>
</mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Elboga</surname> <given-names>U</given-names></name>
<name><surname>Sahin</surname> <given-names>E</given-names></name>
<name><surname>Cayirli</surname> <given-names>YB</given-names></name>
<name><surname>Okuyan</surname> <given-names>M</given-names></name>
<name><surname>Aktas</surname> <given-names>G</given-names></name>
<name><surname>Haydaroglu Sahin</surname> <given-names>H</given-names></name>
<etal/>
</person-group>. 
<article-title>Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in multiple myeloma: Clinical experience</article-title>. <source>Tomogr Ann Arbor Mich</source>. (<year>2022</year>) <volume>8</volume>:<fpage>293</fpage>&#x2013;<lpage>302</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/tomography8010024</pub-id>, PMID: <pub-id pub-id-type="pmid">35202189</pub-id>
</mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>X</given-names></name>
<name><surname>Wang</surname> <given-names>S</given-names></name>
<name><surname>Lai</surname> <given-names>Y</given-names></name>
<name><surname>Wang</surname> <given-names>G</given-names></name>
<name><surname>Wei</surname> <given-names>M</given-names></name>
<name><surname>Jin</surname> <given-names>X</given-names></name>
<etal/>
</person-group>. 
<article-title>Fibroblast activation protein and glycolysis in lymphoma diagnosis: Comparison of<sup>68</sup> ga-FAPI PET/CT and<sup>18</sup> F-FDG PET/CT</article-title>. <source>J Nucl Med</source>. (<year>2023</year>) <volume>64</volume>:<page-range>1399&#x2013;405</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.123.265530</pub-id>, PMID: <pub-id pub-id-type="pmid">37385675</pub-id>
</mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ji</surname> <given-names>M</given-names></name>
<name><surname>Ma</surname> <given-names>G</given-names></name>
<name><surname>Liu</surname> <given-names>C</given-names></name>
<name><surname>Gu</surname> <given-names>B</given-names></name>
<name><surname>Du</surname> <given-names>X</given-names></name>
<name><surname>Ou</surname> <given-names>X</given-names></name>
<etal/>
</person-group>. 
<article-title>Head-to-head comparison of [68Ga]ga-DOTA-FAPI-04 and [18F]FDG PET/CT for the evaluation of tonsil cancer and lymph node metastases: A single-centre retrospective study</article-title>. <source>Cancer Imaging</source>. (<year>2024</year>) <volume>24</volume>:<fpage>56</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40644-024-00699-3</pub-id>, PMID: <pub-id pub-id-type="pmid">38702821</pub-id>
</mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dong</surname> <given-names>A</given-names></name>
<name><surname>Zhao</surname> <given-names>B</given-names></name>
<name><surname>Cheng</surname> <given-names>C</given-names></name>
<name><surname>Zuo</surname> <given-names>C</given-names></name>
</person-group>. 
<article-title>68Ga-FAPI-04 versus 18F-FDG PET/CT in detection of epithelioid Malignant pleural mesothelioma</article-title>. <source>Clin Nucl Med</source>. (<year>2022</year>) <volume>47</volume>:<page-range>980&#x2013;1</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000004269</pub-id>, PMID: <pub-id pub-id-type="pmid">36215397</pub-id>
</mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>L</given-names></name>
<name><surname>Pang</surname> <given-names>Y</given-names></name>
<name><surname>Fang</surname> <given-names>J</given-names></name>
<name><surname>Chen</surname> <given-names>J</given-names></name>
<name><surname>Zhou</surname> <given-names>Y</given-names></name>
<name><surname>Sun</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Design, preclinical evaluation, and clinical translation of 68Ga-FAPI-LM3, a heterobivalent molecule for PET imaging of nasopharyngeal carcinoma</article-title>. <source>J Nucl Med</source>. (<year>2024</year>) <volume>65</volume>:<fpage>394</fpage>&#x2013;<lpage>401</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.123.266183</pub-id>, PMID: <pub-id pub-id-type="pmid">38176714</pub-id>
</mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>J</given-names></name>
<name><surname>Guo</surname> <given-names>X</given-names></name>
<name><surname>Li</surname> <given-names>H</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
<name><surname>Du</surname> <given-names>J</given-names></name>
<name><surname>Zhang</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Regulation of disease signaling by YOD1: Potential implications for therapeutic strategies</article-title>. <source>Cancer Cell Int</source>. (<year>2025</year>) <volume>25</volume>:<page-range>232&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12935-025-03881-0</pub-id>, PMID: <pub-id pub-id-type="pmid">40555982</pub-id>
</mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bai</surname> <given-names>X</given-names></name>
<name><surname>Gao</surname> <given-names>L</given-names></name>
<name><surname>Zhao</surname> <given-names>J</given-names></name>
<name><surname>Liao</surname> <given-names>W</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
<name><surname>Guo</surname> <given-names>X</given-names></name>
<etal/>
</person-group>. 
<article-title>Association between ESR&#x3b1; and ESR&#x3b2; polymorphisms and prostate cancer risk: Meta-analysis</article-title>. <source>Front Oncol</source>. (<year>2025</year>) <volume>15</volume>:<elocation-id>1630363</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2025.1630363</pub-id>, PMID: <pub-id pub-id-type="pmid">41438979</pub-id>
</mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pang</surname> <given-names>Y</given-names></name>
<name><surname>Hao</surname> <given-names>B</given-names></name>
<name><surname>Shang</surname> <given-names>Q</given-names></name>
<name><surname>Sun</surname> <given-names>L</given-names></name>
<name><surname>Chen</surname> <given-names>H</given-names></name>
</person-group>. 
<article-title>Comparison of 68Ga-FAPI and 18F-FDG PET/CT in a patient with cholangiocellular carcinoma: A case report</article-title>. <source>Clin Nucl Med</source>. (<year>2020</year>) <volume>45</volume>:<page-range>566&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RLU.0000000000003056</pub-id>, PMID: <pub-id pub-id-type="pmid">32371618</pub-id>
</mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>H</given-names></name>
<name><surname>Hu</surname> <given-names>Z</given-names></name>
<name><surname>Yang</surname> <given-names>X</given-names></name>
<name><surname>Dai</surname> <given-names>T</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>Comparison of [68Ga]ga-DOTA-FAPI-04 and [18F]FDG uptake in esophageal cancer</article-title>. <source>Front Oncol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>875081</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.875081</pub-id>, PMID: <pub-id pub-id-type="pmid">35785188</pub-id>
</mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bentestuen</surname> <given-names>M</given-names></name>
<name><surname>Al-Obaydi</surname> <given-names>N</given-names></name>
<name><surname>Zacho</surname> <given-names>HD</given-names></name>
</person-group>. 
<article-title>FAPI-avid nonmalignant PET/CT findings: An expedited systematic review</article-title>. <source>Semin Nucl Med</source>. (<year>2023</year>) <volume>53</volume>:<fpage>694</fpage>&#x2013;<lpage>705</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1053/j.semnuclmed.2023.02.001</pub-id>, PMID: <pub-id pub-id-type="pmid">36813670</pub-id>
</mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Duan</surname> <given-names>Y</given-names></name>
<name><surname>Wang</surname> <given-names>X</given-names></name>
<name><surname>Cheng</surname> <given-names>Z</given-names></name>
</person-group>. 
<article-title>Increased 18F-FAPI and 18F-FDG uptake in cardiac tuberculosis mimicking Malignant tumour</article-title>. <source>Eur Heart J - Cardiovasc Imaging</source>. (<year>2024</year>) <volume>26</volume>:<page-range>181&#x2013;1</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/ehjci/jeae266</pub-id>, PMID: <pub-id pub-id-type="pmid">39414250</pub-id>
</mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shou</surname> <given-names>Y</given-names></name>
<name><surname>Xue</surname> <given-names>Q</given-names></name>
<name><surname>Yuan</surname> <given-names>J</given-names></name>
<name><surname>Zhao</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>68Ga-FAPI-04 PET/MR is helpful in differential diagnosis of pancreatitis from pancreatic Malignancy compared to 18F-FDG PET/CT: A case report</article-title>. <source>Eur J Hybrid Imaging</source>. (<year>2021</year>) <volume>5</volume>:<fpage>12</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s41824-021-00106-1</pub-id>, PMID: <pub-id pub-id-type="pmid">34181149</pub-id>
</mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wass</surname> <given-names>G</given-names></name>
<name><surname>Clifford</surname> <given-names>K</given-names></name>
<name><surname>Subramaniam</surname> <given-names>RM</given-names></name>
</person-group>. 
<article-title>Evaluation of the diagnostic accuracy of FAPI PET/CT in oncologic studies: Systematic review and metaanalysis</article-title>. <source>J Nucl Med</source>. (<year>2023</year>) <volume>64</volume>:<page-range>1218&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.123.265471</pub-id>, PMID: <pub-id pub-id-type="pmid">37290798</pub-id>
</mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pang</surname> <given-names>Y</given-names></name>
<name><surname>Zhao</surname> <given-names>L</given-names></name>
<name><surname>Meng</surname> <given-names>T</given-names></name>
<name><surname>Xu</surname> <given-names>W</given-names></name>
<name><surname>Lin</surname> <given-names>Q</given-names></name>
<name><surname>Wu</surname> <given-names>H</given-names></name>
<etal/>
</person-group>. 
<article-title>PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study</article-title>. <source>J Nucl Med Off Publ Soc Nucl Med</source>. (<year>2023</year>) <volume>64</volume>:<page-range>386&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.122.264544</pub-id>, PMID: <pub-id pub-id-type="pmid">36215571</pub-id>
</mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kaplan</surname> <given-names>&#x130;</given-names></name>
<name><surname>Kepenek</surname> <given-names>F</given-names></name>
<name><surname>G&#xfc;zel</surname> <given-names>Y</given-names></name>
<name><surname>Can</surname> <given-names>C</given-names></name>
<name><surname>K&#xf6;mek</surname> <given-names>H</given-names></name>
</person-group>. 
<article-title>The role of 68Ga FAPI-04 and 18F-FDG PET/CT in detecting liver metastases in different types of cancer</article-title>. <source>Nukl - Nucl</source>. (<year>2023</year>) <volume>62</volume>:<page-range>252&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1055/a-2127-7699</pub-id>, PMID: <pub-id pub-id-type="pmid">37595623</pub-id>
</mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname> <given-names>G</given-names></name>
<name><surname>Wang</surname> <given-names>D</given-names></name>
<name><surname>Zhang</surname> <given-names>W</given-names></name>
<name><surname>Jia</surname> <given-names>Z</given-names></name>
<name><surname>Li</surname> <given-names>J</given-names></name>
<name><surname>Zhang</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>Head-to-head comparison of [68Ga]ga-FAPI PET and [18F]FDG PET in the detection of bone and lymph node metastasis in various cancers: A systematic review and meta-analysis</article-title>. <source>Eur J Radiol</source>. (<year>2024</year>) <volume>171</volume>:<elocation-id>111302</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejrad.2024.111302</pub-id>, PMID: <pub-id pub-id-type="pmid">38219352</pub-id>
</mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chi</surname> <given-names>X</given-names></name>
<name><surname>Yang</surname> <given-names>X</given-names></name>
<name><surname>Li</surname> <given-names>G</given-names></name>
<name><surname>Wu</surname> <given-names>H</given-names></name>
<name><surname>Huang</surname> <given-names>J</given-names></name>
<name><surname>Qi</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>A comparative study of 18F-FAPI-42 and 18F-FDG PET/CT for evaluating acute kidney injury in cancer patients</article-title>. <source>Mol Imaging Biol</source>. (<year>2023</year>) <volume>25</volume>:<page-range>671&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11307-023-01820-x</pub-id>, PMID: <pub-id pub-id-type="pmid">37020127</pub-id>
</mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>H</given-names></name>
<name><surname>Pang</surname> <given-names>Y</given-names></name>
<name><surname>Wu</surname> <given-names>J</given-names></name>
<name><surname>Zhao</surname> <given-names>L</given-names></name>
<name><surname>Hao</surname> <given-names>B</given-names></name>
<name><surname>Wu</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Comparison of [68Ga]ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2020</year>) <volume>47</volume>:<page-range>1820&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-020-04769-z</pub-id>, PMID: <pub-id pub-id-type="pmid">32222810</pub-id>
</mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>L</given-names></name>
<name><surname>Zhong</surname> <given-names>J</given-names></name>
<name><surname>Zhang</surname> <given-names>Z</given-names></name>
<name><surname>Ye</surname> <given-names>X</given-names></name>
<name><surname>Wang</surname> <given-names>X</given-names></name>
<name><surname>Liu</surname> <given-names>S</given-names></name>
<etal/>
</person-group>. 
<article-title>Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2024</year>) <volume>51</volume>:<page-range>2012&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-024-06626-9</pub-id>, PMID: <pub-id pub-id-type="pmid">38326656</pub-id>
</mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Giesel</surname> <given-names>FL</given-names></name>
<name><surname>Kratochwil</surname> <given-names>C</given-names></name>
<name><surname>Schlittenhardt</surname> <given-names>J</given-names></name>
<name><surname>Dendl</surname> <given-names>K</given-names></name>
<name><surname>Eiber</surname> <given-names>M</given-names></name>
<name><surname>Staudinger</surname> <given-names>F</given-names></name>
<etal/>
</person-group>. 
<article-title>Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2021</year>) <volume>48</volume>:<page-range>4377&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-021-05307-1</pub-id>, PMID: <pub-id pub-id-type="pmid">34137945</pub-id>
</mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hope</surname> <given-names>TA</given-names></name>
<name><surname>Calais</surname> <given-names>J</given-names></name>
<name><surname>Goenka</surname> <given-names>AH</given-names></name>
<name><surname>Haberkorn</surname> <given-names>U</given-names></name>
<name><surname>Konijnenberg</surname> <given-names>M</given-names></name>
<name><surname>McConathy</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>SNMMI procedure standard/EANM practice guideline for fibroblast activation&#xa0;protein (FAP) PET</article-title>. <source>J Nucl Med</source>. (<year>2025</year>) <volume>66</volume>:<fpage>26</fpage>&#x2013;<lpage>33</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.124.269002</pub-id>, PMID: <pub-id pub-id-type="pmid">39572227</pub-id>
</mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Abbasi</surname> <given-names>S</given-names></name>
<name><surname>Dehghani</surname> <given-names>M</given-names></name>
<name><surname>Khademi</surname> <given-names>S</given-names></name>
<name><surname>Irajirad</surname> <given-names>R</given-names></name>
<name><surname>Pakdin Parizi</surname> <given-names>Z</given-names></name>
<name><surname>Sahebi</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Revolutionizing cancer diagnosis and dose biodistribution: A meta-analysis of [68ga] FAPI- 46 vs. [18f] FDG imaging</article-title>. <source>Syst Rev</source>. (<year>2025</year>) <volume>14</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13643-025-02835-x</pub-id>, PMID: <pub-id pub-id-type="pmid">40349083</pub-id>
</mixed-citation>
</ref>
<ref id="B109">
<label>109</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname> <given-names>K</given-names></name>
<name><surname>Wang</surname> <given-names>L</given-names></name>
<name><surname>Wu</surname> <given-names>H</given-names></name>
<name><surname>Huang</surname> <given-names>S</given-names></name>
<name><surname>Tian</surname> <given-names>Y</given-names></name>
<name><surname>Wang</surname> <given-names>Q</given-names></name>
<etal/>
</person-group>. 
<article-title>18F]FAPI-42 PET imaging in cancer patients: Optimal acquisition time, biodistribution, and comparison with [68Ga]ga-FAPI-04</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2022</year>) <volume>49</volume>:<page-range>2833&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-021-05646-z</pub-id>, PMID: <pub-id pub-id-type="pmid">34893920</pub-id>
</mixed-citation>
</ref>
<ref id="B110">
<label>110</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wegen</surname> <given-names>S</given-names></name>
<name><surname>Claus</surname> <given-names>K</given-names></name>
<name><surname>Linde</surname> <given-names>P</given-names></name>
<name><surname>Rosenbrock</surname> <given-names>J</given-names></name>
<name><surname>Trommer</surname> <given-names>M</given-names></name>
<name><surname>Zander</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>Impact of FAPI-46/dual-tracer PET/CT imaging on radiotherapeutic management in esophageal cancer</article-title>. <source>Radiat Oncol</source>. (<year>2024</year>) <volume>19</volume>:<fpage>44</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13014-024-02430-9</pub-id>, PMID: <pub-id pub-id-type="pmid">38575990</pub-id>
</mixed-citation>
</ref>
<ref id="B111">
<label>111</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname> <given-names>SB</given-names></name>
</person-group>. 
<article-title>The comparative utility of FAPI-based PET radiotracers over [18F]FDG in the assessment of Malignancies</article-title>. <source>Am J Nucl Med Mol Imaging</source>. (<year>2024</year>) <volume>14</volume>:<fpage>190</fpage>&#x2013;<lpage>207</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.62347/JXZI9315</pub-id>, PMID: <pub-id pub-id-type="pmid">39309420</pub-id>
</mixed-citation>
</ref>
</ref-list><glossary>
<title>Glossary</title><def-list><def-item><term><sup>18</sup>F-FDG</term><def>
<p>Fluorine-18 fluorodeoxyglucose</p></def></def-item><def-item><term>AUC</term><def>
<p>Area Under the Curve</p></def></def-item><def-item><term>CAF(s)</term><def>
<p>Cancer-Associated Fibroblast(s)</p></def></def-item><def-item><term>CRC</term><def>
<p>Colorectal Cancer</p></def></def-item><def-item><term>CRS-HIPEC</term><def>
<p>Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy</p></def></def-item><def-item><term>CT</term><def>
<p>Computed Tomography</p></def></def-item><def-item><term>DFSP</term><def>
<p>Dermatofibrosarcoma Protuberans</p></def></def-item><def-item><term>DTC</term><def>
<p>Differentiated Thyroid Cancer</p></def></def-item><def-item><term>EANM</term><def>
<p>European Association of Nuclear Medicine</p></def></def-item><def-item><term>EOC</term><def>
<p>Epithelial Ovarian Cancer</p></def></def-item><def-item><term>FAP</term><def>
<p>Fibroblast Activation Protein</p></def></def-item><def-item><term>FAPI</term><def>
<p>Fibroblast Activation Protein Inhibitor</p></def></def-item><def-item><term>GLUT</term><def>
<p>Glucose Transporter</p></def></def-item><def-item><term>GLUT1</term><def>
<p>Glucose Transporter 1</p></def></def-item><def-item><term>HCC</term><def>
<p>Hepatocellular Carcinoma</p></def></def-item><def-item><term>ICC</term><def>
<p>Intrahepatic Cholangiocarcinoma</p></def></def-item><def-item><term>LDCT</term><def>
<p>Low-Dose Computed Tomography</p></def></def-item><def-item><term>LN</term><def>
<p>Lymph Node</p></def></def-item><def-item><term>LNM</term><def>
<p>Lymph Node Metastasis</p></def></def-item><def-item><term>MRI</term><def>
<p>Magnetic Resonance Imaging</p></def></def-item><def-item><term>NPC</term><def>
<p>Nasopharyngeal Carcinoma</p></def></def-item><def-item><term>NPV</term><def>
<p>Negative Predictive Value</p></def></def-item><def-item><term>NSCLC</term><def>
<p>Non-Small Cell Lung Cancer</p></def></def-item><def-item><term>OC</term><def>
<p>Ovarian Cancer</p></def></def-item><def-item><term>PDAC</term><def>
<p>Pancreatic Ductal Adenocarcinoma</p></def></def-item><def-item><term>PET</term><def>
<p>Positron Emission Tomography</p></def></def-item><def-item><term>PET/CT</term><def>
<p>Positron Emission Tomography/Computed Tomography</p></def></def-item><def-item><term>PET/MR</term><def>
<p>Positron Emission Tomography/Magnetic Resonance</p></def></def-item><def-item><term>PPV</term><def>
<p>Positive Predictive Value</p></def></def-item><def-item><term>RAIR</term><def>
<p>Radioactive Iodine-Refractory</p></def></def-item><def-item><term>ROC</term><def>
<p>Receiver Operating Characteristic</p></def></def-item><def-item><term>SNMMI</term><def>
<p>Society of Nuclear Medicine and Molecular Imaging</p></def></def-item><def-item><term>SRCC</term><def>
<p>Signet Ring Cell Carcinoma</p></def></def-item><def-item><term>SUV</term><def>
<p>Standardized Uptake Value</p></def></def-item><def-item><term>SUVmax</term><def>
<p>Maximum Standardized Uptake Value</p></def></def-item><def-item><term>TBR</term><def>
<p>Tumor-to-Background Ratio</p></def></def-item><def-item><term>TLR</term><def>
<p>Tumor-to-Liver Rati&#xf3;</p></def></def-item><def-item><term>TME</term><def>
<p>Tumor Microenvironment</p></def></def-item><def-item><term>TNM</term><def>
<p>Tumor&#x2013;Node&#x2013;Metastasis</p></def></def-item><def-item><term>VOI</term><def>
<p>Volume of Interest.</p></def></def-item></def-list></glossary>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/957354">Subapriya Suppiah</ext-link>, Putra Malaysia University, Malaysia</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/575375">Hailin Tang</ext-link>, Sun Yat-sen University Cancer Center (SYSUCC), China</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3281809">Sibushi William Serumula</ext-link>, University of KwaZulu-Natal, South Africa</p></fn>
</fn-group>
</back>
</article>